業績 | 東北大学大学院医学系研究科・加藤研究室

原著論文/英文総説

preprint

Suzuki H, Kaneko MK, Kato Y.
A cancer-specific monoclonal antibody against HER2 for breast cancers
Preprint, https://doi.org/10.20944/preprints202309.0906.v1, 2023 (PDF)

submit

Suzuki H, Tanaka T, Kudo Y, Tawara M, Hirayama A, Kaneko MK, Kato Y.
A Rat Anti-Mouse CD39 Monoclonal Antibody for flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 2023 (preprint)
Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Establishment of anti-dog PD-L1 monoclonal antibodies for immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., https://doi.org/10.20944/preprints202308.0725.v1, 2023 (PDF)
Suzuki H, Ohishi T, Nanamiya R, Kawada M, Kaneko MK, Kato Y.
Defucosylated Monoclonal Antibody (H2Mab-139-mG2a-f) Exerted Antitumor Activities in Mouse Xenograft Models of Breast Cancers against Human Epidermal Growth Factor Receptor 2
CIMB, 2023070169, https://www.preprints.org/manuscript/202307.0169/v1, 2023　(PDF)
Tanaka T, Hiroyuki S, Ohishi T, Kaneko MK, Kato Y.
Antitumor activities against breast cancers by an afucosylated anti-HER2 monoclonal antibody H2Mab-77-mG2a-f
Cancer Sci., https://www.preprints.org/manuscript/202307.0900/v1, 2023 (PDF)
Suzuki H, Ohishi T, Kaneko MK, Kato Y.
Humanized and defucosylated antibody against Podoplanin (humLpMab-23-f) exerted antitumor activities in human tumor xenograft models
Cancers, Doi: 10.20944/preprints202308.1756.v1, 2023 (PDF)
Arimori T, Mihara E, Suzuki H, Ohishi T, Tanaka T, Kaneko MK, Takagi J, Kato Y.
Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies
Cell Press Community Review, 2023 (PDF)

revision

Yoneda H, Mitsuhashi A, Yoshida A, Ogino H, Itakura S, Nguyen NT, Nokihara H, Sato S, Shinohara T, Hanibuchi M, Abe S, Kaneko MK, Kato Y, Nishioka Y.
Anti-podoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells
Cancer Sci., 2023
Yamada K, Shioya R, Nishino K, Furihata H, Hijikata A, Kaneko MK, Kato Y, Shirai T, Kosako H, Sawasaki T.
Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding
Nat comm., DOI: 10.21203/rs.3.rs-2522335/v1, 2023

Cai X, Ito S, Noi K, Inoue M, Ushioda R, Kato Y, Nagata K, Inaba K.
Mechanistic characterization of disulfide bond reduction of an ERAD substrate mediated by cooperation between ERdj5 and BiP
Journal of Biological Chemistry, 2023
Nanamiya R, Suzuki H, Kaneko MK, Kato Y.
Development of an Anti−EphB4 Monoclonal Antibody for Multiple Applications against Breast Cancers
Monoclon. Antib. Immunodiagn. Immunother., https://www.preprints.org/manuscript/202307.1288/v1, 2023 (PDF)
Okada Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-Mouse CD39 Monoclonal An-tibody (C39Mab-1) for Flow Cytometry and Western Blot Anal-yses
Monoclon. Antib. Immunodiagn. Immunother., 2023 (preprint)
Okagawa T, Konnai S, Goto S, Sajiki Y, Ganbaatar O, Watari K, Nakamura H, Wang CX, Tachibana T, Kato Y, Kameda Y, Kohara J, Terasaki N, Kubota M, Takeda A, Takahashi H, Suzuki Y, Maekawa N, Murata S, Ohashi K.
Development of a high-affinity anti-bovine PD-1 rabbit–bovine chimeric antibody using an efficient selection and large production system
Veterinary Research, 2023
Maekawa N, Konnai S, Hosoya K, Kim S, Kinoshita R, Deguchi T, Owaki R, Tachibana Y, Yokokawa M, Takeuchi H, Kagawa Y, Takagi S, Ohta H, Kato Y, Yamamoto S, Yamamoto K, Suzuki Y, Okagawa Y, Murata S, Ohashi K.
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
PLoS ONE, 2023

online

Goto N, Suzuki H, Zheng L, Okano Y, Okita Y, Watanabe Y, Kato Y, Kato M.
Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation.
Cancer Sci., http://doi.org/10.1111/cas.15934, 2023 (PDF)
Shinada M, Kato D, Tsuboi M, Ikeda N, Aoki S, Iguchi T, Li T, Kodera Y, Ota R, Koseki S, Shibahara H, Takahashi Y, Hashimoto Y, Chambers J, Uchida K, Noguchi S, Kato Y, Nishimura R, Nakagawa T.
Podoplanin promotes cell proliferation, survival, and migration of canine non-tonsillar squamous cell carcinoma
The Journal of Veterinary Medical Science, https://doi.org/10.1292/jvms.23-0062, 2023
Shinada M, Kato D, Motegi T, Tsuboi M, Ikeda N, Aoki S, Iguchi T, Li T, Kodera Y, Ota R, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kato Y, Nishimura R, Nakagawa T.
Podoplanin drives amoeboid invasion in canine and human mucosal melanoma
Mol Cancer Res., https://doi.org/10.1158/1541-7786.MCR-22-0929, 2023

2023

365. Tanaka T, Kitamura K, Suzuki H, Kaneko MK, Kato Y.
Establishment of a Novel Anti-Human CCR6 Monoclonal Antibody C6Mab-19 with the High Binding Affinity in Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 42(4), 117–124, https://doi.org/10.1089/mab.2023.0004, 2023 (preprint; PDF)
364. Ouchida T, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry
Int. J. Transl. Med., 3(3), 310-320; 2023 (PDF)
363. Han BB, Watanabe S, Nomura N, Liu K, Uemura T, Inoue M, Tsutsumi A, Fujita H, Kinoshita K, Kato Y, Iwata S, Kikkawa M, Inaba K.
Cryo-EM structures of human zinc transporter ZnT7 reveal the mechanism of Zn2+ uptake into the Golgi apparatus
Nat comm., 14, 4770, doi: https://doi.org/10.1101/2022.03.23.485435, 2023 (PDF)
362. Suzuki H, Goto N, Tanaka T, Ouchida T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 8 Monoclonal Antibody C44Mab-94 against Gastric Carcinomas
antibodies, 12(3), 45; https://doi.org/10.3390/antib12030045, 2023 (PDF)
361. Ishikawa K, Suzuki H, Kaneko MK, Kato Y.
A Novel Anti-CD44 Variant 10 Monoclonal Antibody is Useful for Immunohistochemical Analysis against Oral Squamous cell carcinomas
Curr. Issues Mol. Biol., 45(7), 5248-5262; https://doi.org/10.3390/cimb45070333, 2023 (PDF)
360. Goto N, Suzuki H, Tanaka T, Ishikawa K, Ouchida T, Kaneko MK, Kato Y.
EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry
antibodies, 12(3), 42, https://doi.org/10.3390/antib12030042, 2023 (PDF)
359. Deguchi T, Maekawa N, Konnai S, Owaki R, Hosoya K, Morishita K, Nakamura M, Okagawa T, Takeuchi H, Kim S, Kinoshita R, Tachibana Y, Ykokawa M, Takagi S, Kato Y, Suzuki Y, Murata S, Ohashi K.
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
Cancers, 15(11), 3013; https://doi.org/10.3390/cancers15113013, 2023 (PDF)
358. Murate M, Yokoyama N, Tomishige N, Richert L, Humbert N, Pollet B, Makino A, Kono N, Mauri L, Aoki J, Sako Y, Sonnino S, Komura N, Ando H, Kaneko MK, Kato Y, Inamori KI, Inokuchi JI, Mély Y, Iwabuchi K, Kobayashi T.
Cell density-dependent membrane distribution of ganglioside GM3 in melanoma cells
Cell. Mol. Life Sci., 80(6):167. doi: 10.1007/s00018-023-04813-9, 2023 (PDF)
357. Tiyamanee W, Konnai S, Okagawa T, Nojima Y, Ganbaatar O, Maekawa N, Hasebe R, Kagawa Y, Kato Y, Suzuki Y, Murata S, Ohashi K.
Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in sheep
Vet Immunol Immunopathol., 261, 110609, https://doi.org/10.1016/j.vetimm.2023.110609, 2023 (PDF)
356. Adachi Y, Kaneko MK, Kato Y, Nogi T.
Recombinant production of antibody antigen-binding fragments with an N-terminal human growth hormone tag in mammalian cells
Protein Expr Purif., 208–209, 106289, https://doi.org/10.1016/j.pep.2023.106289, 2023 (PDF)
355. Suzuki H, Kitamura K, Goto N, Ishikawa K, Ouchida T, Tanaka T, Kaneko MK, Kato Y.
A Novel Anti-CD44 Variant 3 Monoclonal Antibody C44Mab-6 was Established for Multiple Applications
Int. J. Mol. Sci., 24(9), 8411; https://doi.org/10.3390/ijms24098411, 2023 (PDF)
354. Tanaka T, Tawara M, Suzuki H, Kaneko MK, Kato Y.
Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) Using 1× Alanine Scanning
antibodies, 12(2), 32; https://doi.org/10.3390/antib12020032, 2023 (PDF)
353. Kudo Y, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C44Mab-3 for Multiple Applications against Pancreatic Carcinomas
antibodies, 12(2), 31, https://doi.org/10.3390/antib12020031, 2023 (PDF)
352. Isoda Y, Tanaka Y, Suzuki H, Kitamura K, Kudo Y, Ejima R, Ozawa K, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of the Novel Anti-human CCR9 Monoclonal Antibody (C9Mab-11) by 2 × Alanine Scanning
Monoclon. Antib. Immunodiagn. Immunother., 42(2), 73–76, https://doi.org/10.1089/mab.2022.0035, 2023 (PDF)
351. Tateyama N, Tanaka T, Isoda T, Okada Y, Kobayashi H, Li G, Nanamiya R, Yoshikawa T, Kaneko MK, Suzuki H, Kato Y.
Epitope Mapping of Anti-mouse CCR3 Monoclonal Antibodies (C3Mab-6 and C3Mab-7)
Monoclon. Antib. Immunodiagn. Immunother., 42(2), 68–72, https://doi.org/10.1089/mab.2022.0034, 2023 (PDF)
350. Nishibori S, Kaneko MK, Nakagawa T, Nishigaki K, Kato Y, Igase M, Mizuno T.
Development of anti-feline PD-1 antibody and its functional analysis
Sci Rep., 13, 6420,doi: 10.1038/s41598-023-31543-6, 2023 (PDF)
349. Tawara M, Suzuki H, Goto N, Tanaka T, Kaneko MK, Kato Y.
A Novel Anti-CD44 Variant 9 Monoclonal Antibody C44Mab-1 was Developed for Immunohistochemical Analyses Against Colorectal Cancers
Curr. Issues Mol. Biol., 45(4), 3658-3673, doi: 10.3390/cimb45040238, 2023 (PDF)
348. Suzuki H, Ozawa K, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 Variant 7/8 Monoclonal Antibody C44Mab-34 for Multiple Applications against Oral Carcinomas
Biomedicines, 11(4), 1099; https://doi.org/10.3390/biomedicines11041099, 2023 (PDF)
347. Okagawa T, Konnai S, Nakamura H, Ganbaatar O, Sajiki Y, Watari K, Noda H, Honma M, Kato Y, Suzuki Y, Maekawa N, Murata S, Ohashi K.
Enhancement of Vaccine-Induced T-Cell Responses by PD-L1 Blockade in Calves
Vaccines, 11(3), 559; https://doi.org/10.3390/vaccines11030559, 2023 (PDF)
346. Li G, Suzuki H, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-EpCAM Monoclonal Antibody (EpMab-37) using the Alanine Scanning Method
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 41–47, doi: 10.1089/mab.2022.0031, 2023 (PDF)
345. Kobayashi H, Suzuki H, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
Establishment of a Sensitive Monoclonal Antibody against Mouse CCR9 (C9Mab-24) for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 15–21, https://doi.org/10.1089/mab.2022.0032, 2023 (PDF)
344. Nanamiya R, Ohishi T, Suzuki H, Mizuno T, Yoshikawa T, Tanaka T, Kaneko MK, Kato Y.
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody (H77Bf) exerts antitumor activities in mouse xenograft models of canine osteosarcoma
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 27–33, doi:10.1089/mab.2022.0022, 2023 (PDF)
343. Suzuki H, Ohishi T, Yoshikawa T, Suzuki H, Mizuno T, Tanaka T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf)
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 34–40, doi: 10.1089/mab.2022.0023, 2023 (PDF)
342. Isoda Y, Tanaka T, Suzuki H, Yoshikawa T, Kitamura K, Kudo Y, Ejima R, Ozawa K, Kaneko MK, Kato Y.
Epitope Mapping using the Cell-Based 2×Alanine Substitution Method about the Anti-mouse CXCR6 Monoclonal Antibody, Cx6Mab-1
Monoclon. Antib. Immunodiagn. Immunother., 42(1), 22–26, doi: 10.1089/mab.2022.0029, 2023 (PDF)
341. Suzuki H, Tanaka T, Goto N, Kaneko MK, Kato Y.
Development of a novel anti-CD44 variant 4 monoclonal antibody C44Mab-108 for immunohistochemistry
Curr. Issues Mol. Biol., 45(3), 1875-1888; https://doi.org/10.3390/cimb45030121, 2023 (PDF)
340. Ejima R, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-CD44 variant 6 Monoclonal Antibody C44Mab-9 for Multiple Applications against Colorectal Carcinomas
Int. J. Mol. Sci., 24(4), 4007; https://doi.org/10.3390/ijms24044007, 2023 (PDF)
339. Nakamura H, Konnai S, Okagawa T, Maekawa N, Sajiki Y, Watari K, Kamitani K, Saito M, Kato Y, Suzuki Y, Murata S, Ohashi K.
Combined immune checkpoint blockade enhances antiviral immunity against bovine leukemia virus
J Virol., 97(1), e0143022., doi: 10.1128/jvi.01430-22., 2023 (PDF)
338. Kobayashi H, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Determination of the Binding Epitope of an Anti-mouse CCR9 Monoclonal Antibody (C9Mab-24) using the 1 × alanine and 2 × alanine-substitution Method
antibodies, 12(1), 11; https://doi.org/10.3390/antib12010011, 2023 (PDF)
337. Maekawa N, Konnai S, Otsuka T, Aoki E, Takeuchi H, Kato Y, Kaneko MK, Yamada S, Kagawa Y, Nishimura M, Takagi S, Deguchi T, Ohta H, Nakagawa T, Suzuki Y, Okagawa T, Murata S, Ohashi K.
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
PLoS One, 18(1):e0281143. doi: 10.1371/journal.pone.0281143, 2023 (PDF)
336. Li G, Suzuki H, Ohishi T, Tanaka T, Yanaka M, Nakamura T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Antitumor activities by a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models
Int J Mol Med, 51(2), 18, https://doi.org/10.3892/ijmm.2023.5221, 2023 (PDF)
335. Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M.
Current targeted therapy for metastatic colorectal cancer
Int. J. Mol. Sci. , 24(2), 1702; https://doi.org/10.3390/ijms24021702, 2023 (PDF)

2022

334. Tanaka T, Suzuki H, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Development of a Novel Anti-Mouse CCR6 Monoclonal Antibody (C6Mab-13) by N-Terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 343–349, doi: 10.1089/mab.2022.0021, 2022 (PDF)
333. Tanaka T, Suzuki H, Li G, Nanamiya R, Tateyama N, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope mapping of an Anti-Mouse CCR2 Monoclonal Antibody (C2Mab-6) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 339–342, doi:10.1089/mab.2022.0020, 2022 (PDF)
332. Saito M, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow cytometry and Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 333–338, https://doi.org/10.1089/mab.2021.0069, 2022 (PDF)
331. Kawabata H, Ohishi T, Suzuki H, Kawada M, Suzuki H, Kaneko MK, Kato Y.
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of Renal Cell Cancers
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 320–327, https://doi.org/10.1089/mab.2021.0049, 2022 (PDF)
330. Nanamiya R, Suzuki H, Takei J, Li G, Goto N, Harada H, Saito M, Tanaka T, Kaneko MK, Kato Y.
Development of Monoclonal Antibody 281-mG2a-f Against Golden Hamster Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 311–319, https://doi.org/10.1089/mab.2021.0058, 2022 (PDF)
329. Tanaka T, Suzuki H, Isoda Y, Nakamura T, Yanaka M, Handa S, Takahashi N, Okuno S, Yoshikawa T, Li G, Nanamiya R, Goto N, Tateyama N, Okada Y, Kobayashi H, Kaneko MK, Kato Y.
Development of a Sensitive Anti-human CCR9 Monoclonal Antibody (C9Mab-11) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(6), 303–310, doi: 10.1089/mab.2022.0027, 2022 (PDF)
328. Yamamoto Y, Inoue T, Inoue M, Murae M, Fukasawa M, Kaneko MK, Kato Y, Noguchi K.
SARS-Cov-2 Spike Protein Mutation at Cysteine-488 Impairs Its Golgi Localization And Intracellular S1/S2 Processing
Int. J. Mol. Sci., 23(24), 15834; https://doi.org/10.3390/ijms232415834, 2022 (PDF)
327. Machitani M, Takei J, Kaneko MK, Ueki S, Ohashi H, Watashi K, Kato Y, Masutomi K.
Development of novel monoclonal antibodies against nsp12 of SARS-CoV-2
Virol J., 19(1):213. doi: 10.1186/s12985-022-01948-2, 2022 (PDF)
326. Tateyama N, Suzuki H, Li G, Yoshikawa T, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of Anti-mouse CCR3 Monoclonal Antibodies using Flow Cytometry
antibodies, 11(4), 75; https://doi.org/10.3390/antib11040075, 2022 (PDF)
325. Tanaka T, Suzuki H, Li G, Ohishi T, Kawada M, Yoshikawa T, Kaneko MK, Kato Y.
A Defucosylated Anti-EpCAM Monoclonal Antibody (Ep-Mab-37-mG2a-f) Exerts Antitumor Activity in Xenograft Model
antibodies, 11(4), 74; https://doi.org/10.3390/antib11040074, 2022 (PDF)
324. Tateyama N, Suzuki H, Ohishi T, Tanaka T, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activity of an anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
pharmaceutics,14(11), 2494; https://doi.org/10.3390/pharmaceutics14112494, 2022 (PDF)
323. Sasaki E, Iwakoshi A, Satake T, Nakajima K, Kobayashi M, Ando Y, Koshikawa T, Masago K, Honma N, Nishimura R, Kato Y, Ichihara S.
The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma with Reversed Polarity of the Breast
Appl Immunohistochem Mol Morphol, 30(10):654-661,　doi: 10.1097/PAI.0000000000001074, 2022　(PDF)
322. Isoda Y, Tanaka T, Suzuki H, Nakamura T, Yanaka M, Handa S, Komatsu Y, Okuno S, Takahashi N, Okada Y, Kobayashi H, Li G, Nanamiya R, Goto N, Tateyama N, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-mouse CXCR6 Monoclonal Antibody (Cx6Mab-1) using the 2×Alanine scanning method
Monoclon. Antib. Immunodiagn. Immunother.,41(5),275–278, DOI: 10.1089/mab.2022.0019, 2022 (PDF)
321. Tanaka T, Suzuki H, Li G, Nanamiya R, Isoda Y, Okada Y, Kobayashi H, Yoshikawa T, Kaneko MK, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody (K036C2)
Monoclon. Antib. Immunodiagn. Immunother.,41(5),285–289, DOI: 10.1089/mab.2022.0018, 2022 (PDF)
320. Saito M, Suzuki H, Tanaka T, Yoshikawa T, Kaneko MK, Kato Y.
KLMab-1: An Anti-Human KLRG1 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother.,41(5),279–284, https://doi.org/10.1089/mab.2022.0016, 2022 (PDF)
319. Sajiki Y, Konnai S, Watari K, Okagawa T, Tanaka A, Kawaji S, Nagata R, Maekawa N, Suzuki Y, Kato Y, Murata S, Mori Y, Ohashi K.
Prostaglandin E2-Induced Immune Suppression via Cytotoxic T-Lymphocyte Antigen 4 in Paratuberculosis
Infect Immun ;90(10):e0021022, doi: 10.1128/iai.00210-22. 2022　(PDF)
318. Ishikawa A, Waseda M, Ishii T, Kaneko MK, Kato Y, Kaneko S.
Improved anti-solid tumor response by humanized anti-podoplanin chimeric antigen receptor transduced human cytotoxic T cells in animal model
Genes Cells,27(9), 549-558, https://doi.org/10.1111/gtc.12972, 2022 (PDF)
317. Tanaka T, Li G, Saito M, Suzuki H, Kaneko MK, Kato Y.
Development of an Anti-human CCR2 Monoclonal Antibody (C2Mab-9) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 188–193, https://doi.org/10.1089/mab.2022.0001, 2022 (PDF)
316. Kudo Y, Suzuki H, Kaneko MK, Kato Y.
Development of a Monoclonal Antibody PMab-295 Against Elephant Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 194–201, https://doi.org/10.1089/mab.2022.0007, 2022 (PDF)
315. Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Identification of the Binding Epitope of an Anti-Mouse CCR4 Monoclonal Antibody, C4Mab-1
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 214–220, https://doi.org/10.1089/mab.2022.0015, 2022 (PDF)
314. Okada Y, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Elephant Podoplanin Monoclonal Antibody (PMab-295) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother., 41(4), 221–227, https://doi.org/10.1089/mab.2022.0017, 2022 (PDF)
313. Imaizumi Y, Takanuki K, Miyake T, Takemoto M, Hirata K, Hirose M, Oi R, Kobayashi T, Miyoshi K, Aruga R, Yokoyama T, Katagiri S, Matsuura H, Iwasaki K, Kato T, Kaneko MK, Kato Y, Tajiri M, Akashi S, Nureki O, Hizukuri Y, Akiyama Y, Nogi T.
Mechanistic insights into intramembrane proteolysis by E. coli site-2 protease homolog RseP
Sci Adv.,8(34):eabp9011, DOI: 10.1126/sciadv.abp9011, 2022 (PDF)
312. Fujii K, Morita S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, Yamaguchi K, Abe J, Yamazaki T, Imai T, Sugamura K, Yasuda J, Satoh K, Sato I, Saito-Koyama R, Fujishima F, Sasano H, Kato Y, Matsuura K, Asada Y, Tamai K.
Establishment of a monoclonal antibody against glycosylated CD271 specific for cancer cells in immunohistochemistry
Cancer Sci., 113(8),2878-2887, doi: 10.1111/cas.15340., 2022 (PDF)
311. Chalise L, Kato A, Ohno M, Maeda S, Yamamichi A, Kuramitsu S, Shiina S, Takahashi H, Ozone S, Yamaguchi J, Kato Y, Rockenbach Y, Natsume A, Todo T.
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47delta combination therapy against glioblastoma
Mol Ther Oncolytics, 26, 265-274, https://doi.org/10.1016/j.omto.2022.07.006, 2022 (PDF)
310. Suzuki H, Ohishi T, Tanaka T, Saito M, Mizuno T, Yoshikawa T, Kawada M, Kaneko MK, Kato Y.
Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
Oncol. Rep.,,48(3), 154, https://doi.org/10.3892/or.2022.8366, 2022 (PDF)
309. Saito M, Suzuki H, Kaneko MK, Kato Y.
TgMab-2: An Anti-Human TIGIT Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 157–162, https://doi.org/10.1089/mab.2022.0013, 2022 (PDF)
308. Tanaka T, Li G, Kaneko MK, Suzuki H, Kato Y.
Epitope Mapping of the Anti-Human CCR2 Monoclonal Antibody C2Mab-9
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 150–156, https://doi.org/10.1089/mab.2022.0012, 2022 (PDF)
307. Tanaka T, Ohishi T, Saito M, Suzuki H, Kaneko MK, Kawada M, Kato Y.
Defucosylated Anti-EGFR Monoclonal Antibody Exerted Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor
Monoclon. Antib. Immunodiagn. Immunother. 41(3), 142–149, https://doi.org/10.1089/mab.2022.0009, 2022 (PDF)
306. Goto N, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Chinese/golden Hamster Podoplanin Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 163–169, https://doi.org/10.1089/mab.2022.0014, 2022 (PDF)
305. Kitamura K, Suzuki H, Kaneko MK, Kato Y.
Cx6Mab-1: a Novel Anti-mouse CXCR6 Monoclonal Antibody established by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(3), 133–141, https://doi.org/10.1089/mab.2022.0010, 2022 (PDF)
304. Alam M, Shima H, Matsuo Y, Nguyen CL, Matsumoto M, Ishii Y, Sato N, Sugiyama T, Nobuta R, Hashimoto S, Liu L, Kaneko MK, Kato Y, Inada T, Igarashi K.
mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine
J Biol Chem, 298(7),102084, doi: 10.1016/j.jbc.2022.102084., 2022 (PDF)
303. Li G, Suzuki H, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
Development of A Novel Anti-EpCAM Monoclonal Antibody for Various Applications
Antibodies, 11(2), 41; https://doi.org/10.3390/antib11020041, 2022 (PDF) (Preprint)
302. Maekawa N, Konnai S, Asano Y, Sajiki Y, Deguchi T, Okagawa T, Watari K, Takeuchi H, Takagi S, Hosoya K, Kim S, Ohta H, Kato Y, Suzuki Y, Murata S, Ohashi K.
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
Sci. Rep.,12(1):9265. doi: 10.1038/s41598-022-13484-8., 2022 (PDF)
301. Goto N, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a novel anti-CD44 monoclonal antibody for multiple applications against esophageal squamous cell carcinomas
Int. J. Mol. Sci., 23(10), 5535; https://doi.org/10.3390/ijms23105535, 2022 (PDF) (Preprint)
300. Matsuda Y, Yamashita T, Ye J, Yasukawa M, Yamakawa K, Mukai Y, Machitani M, Daigo Y, Miyagi Y, Yokose T, Oshima T, Ito H, Morinaga S, Kishida T, Minamoto T, Yamada S, Takei J, Kaneko MK, Kojima M, Kaneko S, Masaki T, Hirata M, Haba R, Kontani K, Kanaji N, Miyatake N, Okano K, Kato Y, Masutomi K.
Phosphorylation of hTERT at threonine 249 is a novel tumor biomarker of aggressive cancer with poor prognosis in multiple organs
J Pathol, 257(2), 172-185, doi: 10.1002/path.5876, 2022 (PDF)
299. Tanaka T, Li G, Saito M, Kaneko MK, Suzuki H, Kato Y.
Development of a Novel Anti-mouse CCR2 Monoclonal Antibody (C2Mab-6) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 80–86, DOI: 10.1089/mab.2021.0063, 2022 (PDF)
298. Goto N, Suzuki H, Ohishi T, Harakawa A, Li G, Saito M, Takei J, Tanaka T, Sano M, Kawada M, Kaneko MK, Kato Y.
Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-EGFR Monoclonal Antibody
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 67–73, DOI: 10.1089/mab.2021.0059, 2022 (PDF)
297. Suzuki H, Saito M, Tanaka T, Kitamura K, Kudo Y, Kaneko MK, Kato Y.
C8Mab-3: an Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 110–114, DOI: 10.1089/mab.2022.0002, 2022 (PDF)
296. Li G, Suzuki H, Takei J, Sano M, Tanaka T, Harada H, Mizuno T, Ohishi T, Kawada M, Kaneko MK, Kato Y.
Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody (E134Bf)
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 53–58, https://doi.org/10.1089/mab.2021.0040, 2022 (PDF)
295. Kawabata H, Suzuki H, Ohishi T, Kawada M, Kaneko MK, Kato Y.
A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG2a-f) Exerts Antitumor Activity in a Mouse Xenograft Model of CD10-overexpressed Tumors
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 59–66, https://doi.org/10.1089/mab.2021.0048, 2022 (PDF)
294. Suzuki H, Tanaka T, Saito M, Li G, Goto N, Nanamiya R, Kaneko MK, Kato Y.
C3Mab-3: A Monoclonal Antibody for mouse CCR3 for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 74–79, https://doi.org/10.1089/mab.2021.0062, 2022 (PDF)
293. Saito M, Tanaka T, Nakamura T, Yanaka M, Handa S, Komatsu Y, Harigae Y, Tateyama N, Nanamiya R, Li G, Suzuki H, Kaneko MK, Kato Y.
C8Mab-2: An Anti-Mouse C–C Motif Chemokine Receptor 8 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 115–119, https://doi.org/10.1089/mab.2021.0045, 2022 (PDF)
292. Takei J, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a Novel Anti-mouse CCR4 Monoclonal Antibody (C4Mab-1) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 87–934, https://doi.org/10.1089/mab.2021.0064, 2022 (PDF)
291. Saito M, Suzuki H, Harigae Y, Li G, Tanaka T, Kaneko MK, Kato Y.
C9Mab-1: An Anti-Human CCR9 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 120–124, https://doi.org/10.1089/mab.2021.0052, 2022 (PDF)
290. Suzuki H, Goto N, Tanaka T, Kaneko MK, Kato Y.
Establishment of Novel Anti-mouse CCR3 Monoclonal Antibodies (C3Mab-6 and C3Mab-7) by N-terminal Peptide Immunization
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 94–100, https://doi.org/10.1089/mab.2021.0065, 2022 (PDF)
289. Goto N, Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Development of a Monoclonal Antibody PMab-292 Against Ferret Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 41(2), 101–109, DOI: 10.1089/mab.2021.0067, 2022 (PDF)
288. Saito M, Harigae Y, Li G, Tanaka T, Suzuki H, Kaneko MK, Kato Y.
C3Mab-2: An Anti-Mouse CCR3 Monoclonal Antibody for Immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 45–49, DOI: 10.1089/mab.2021.0050, 2022 (PDF)
287. Li G, Suzuki H, Takei J, Saito M, Goto N, Uchida K, Nakagawa T, Harada H, Tanaka T, Kaneko MK, Kato Y.
Immunohistochemical Analysis using Monoclonal Antibody PMab-269 against Steller Sea Lion Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 39–44, DOI: 10.1089/mab.2021.0055, 2022 (PDF)
286. Kawabata H, Suzuki H, Takei J, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-CD10 Monoclonal Antibody (MME/1870) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 15–19, DOI: 10.1089/mab.2021.0046, 2022 (PDF)
285. Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of Rituximab using HisMAP Method
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 8–14, DOI: 10.1089/mab.2021.0044, 2022 (PDF)
284. Nanamiya R, Takei J, Ohishi T, Tanaka T, Sano M, Nakamura T, Yanaka M, Handa S, Tateyama N, Harigae Y, Saito M, Suzuki H, Kawada M, Kaneko MK, Kato Y.
Defucosylated Anti-EGFR Monoclonal Antibody (134-mG2a-f) Exerts Antitumor Activities in Mouse Xenograft Models of Canine Osteosarcoma
Monoclon. Antib. Immunodiagn. Immunother., 41(1), 1–7, DOI: 10.1089/mab.2021.0036, 2022 (PDF)
283. Tanaka T, Ohishi T, Saito M, Kawada M, Kaneko MK, Kato Y.
TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 32–38, DOI: 10.1089/mab.2021.0056, 2022 (PDF)
282. Suzuki H, Tanaka T, Kaneko MK, Kato Y.
Epitope Mapping of the Anti-CD20 Monoclonal Antibodies (C20Mab-11 and 2H7) using HisMAP method
Monoclon. Antib. Immunodiagn. Immunother.,41(1), 20–26, DOI: 10.1089/mab.2021.0051, 2022 (PDF)
281. Suzuki H, Kaneko MK, Kato Y.
Roles of Podoplanin in Malignant Progression of Tumor
Cells, 11(3), 575; https://doi.org/10.3390/cells11030575, 2022 (PDF)
(Preprint, doi: 10.20944/preprints202201.0280.v1, 2022)
280. Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I.
Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas
Brain Tumor Pathol., 39, pages 14–24, doi: 10.1007/s10014-021-00418-x, 2022 (PDF)
279. Watari K, Konnai S, Maekawa N, Okagawa T, Sajiki Y, Kato Y, Suzuki Y, Murata S, Ohashi K.
Enhancement of interleukin-2 production by bovine peripheral blood mononuclear cells treated with the combination of anti-programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 chimeric monoclonal antibodies
J Vet Med Sci, 84(1), 6-15, doi: 10.1292/jvms.21-0552, 2022 (PDF)

2021

278. Takei J, Suzuki H, Li G, Saito M, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-CD20 Monoclonal Antibody (C20Mab-60) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother.,40(6), 250–254, https://doi.org/10.1089/mab.2021.0042, 2021 (PDF)
277. Takei J, Li G, Saito M, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Human CCR9 Monoclonal Antibody (C9Mab-1) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother.,40(6), 239–242, https://doi.org/10.1089/mab.2021.0037, 2021 (PDF)
276. Nakano T, Tanaka T, Sakane F, Kaneko MK, Kato Y, Goto K.
Immunocytochemical Analysis of DGKh in Cultured Cells using a Monoclonal Antibody DhMab-4
Monoclon. Antib. Immunodiagn. Immunother.,40(6), 261–265, https://doi.org/10.1089/mab.2021.0034, 2021 (PDF)
275. Takei J, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-HER2 Monoclonal Antibody (H2Mab-181) using Enzyme-Linked Immunosorbent Assay
Monoclon. Antib. Immunodiagn. Immunother.,40(6), 255–260, DOI: 10.1089/mab.2021.0029, 2021 (PDF)
274. Takei J, Furusawa Y, Saito M, Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-CD20 Monoclonal Antibody (C20Mab-60) using the HisMAP Method
Monoclon. Antib. Immunodiagn. Immunother.,40(6), 243–249, DOI: 10.1089/mab.2021.0035, 2021 (PDF)
273. Li G, Ohishi T, Kaneko MK, Takei J, Mizuno T, Kawada M, Saito M, Suzuki H, Kato Y.
Defucosylated Mouse–Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors
Cells, 10(12), 3599; https://doi.org/10.3390/cells10123599, 2021 (PDF)
272. Kamoto S, Shinada M, Kato D, Tsuboi M, Yoshimoto S, Yoshitake R, Eto S, Ikeda N, Takahashi Y, Hashimoto Y, Chambers J, Uchida K, Yamada S, Kaneko MK, Nishimura R, Kato Y, Nakagawa T.
Expression of podoplanin in various types of feline tumor tissues.
J Vet Med Sci, 83(11),1795-1799, https://doi.org/10.1292/jvms.20-0608, 2021 (PDF)
271. Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Ichikawa Y, Kobayashi A, Shibahara T, Yanagawa Y, Higuchi H, Kato Y, Suzuki Y, Murata S, Ohashi K.
Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade
Immun Inflamm Dis., 9(4), 1573-1583, doi: 10.1002/iid3.510, 2021 (PDF)
270. Takei J, Suzuki H, Kaneko MK, Kato Y.
Epitope mapping of the anti-CD44 monoclonal antibody (C44Mab-46) using alanine-scanning mutagenesis and surface plasmon resonance
Monoclon. Antib. Immunodiagn. Immunother.,40(5), 219-226, DOI: 10.1089/mab.2021.0028, 2021 (PDF)
269. Suzuki H, Kaneko MK, Kato Y.
Epitope Mapping of a Cancer-specific Anti-podocalyxin Monoclonal Antibody (PcMab-60) using Enzyme-linked Immunosorbent Assay and Surface Plasmon Resonance
Monoclon. Antib. Immunodiagn. Immunother., 40(5), 227-232, DOI: 10.1089/mab.2021.0030, 2021 (PDF)
268. Sudo H, Tsuji AB, Sugyo A, Kaneko MK, Kato Y, Nagatsu K, Suzuki H, Higashi T.
Preclinical evaluation of podoplanin-targeted al-pha-radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma
Cells, 10(10), 2503; https://doi.org/10.3390/cells10102503, 2021 (PDF)
267. Tateyama N, Ohishi T, Takei J, Hosono H, Nanamiya R, Tanaka T, Sano M, Saito M, Kawada M, Kaneko MK, Kato Y.
An Anti‐HER2 Monoclonal Antibody H2Mab‐41 Exerts Antitumor Activities in Mouse Xenograft Model using Dog HER2‐overexpressed Cells
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 184–190, DOI: 10.1089/mab.2021.0025, 2021　(PDF)
266. Tateyama N, Nanamiya R, Ohishi T, Takei J, Nakamura T, Yanaka M, Hosono H, Saito M, Tanaka T, Sano M, Kawada M, Kaneko MK, Kato Y.
Defucosylated Anti-EGFR Monoclonal Antibody 134-mG2a-f Exerts Antitumor Activities in Mouse Xenograft Models of Dog EGFR-overexpressed Cells
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 177–183, DOI: 10.1089/mab.2021.0022, 2021　(PDF)
265. Kaneko MK, Kato Y.
Development of a novel epitope mapping system: RIEDL insertion for epitope mapping method
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 162–167, DOI: 10.1089/mab.2021.0023, 2021　(PDF)
264. Nanamiya R, Sano M, Yanaka M, Nakamura T, Saito M, Tanaka T, Hosono H, Tateyama N, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-Human EGFR Monoclonal Antibody (EMab-51) using the REMAP Method
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 149–155, DOI: 10.1089/mab.2021.0010, 2021　(PDF)
263. Takei J, Tanaka T, Sano M, Hosono H, Nanamiya R, Tateyama N, Saito M, Suzuki H, Harada H, Kaneko MK, Kato Y.
Development of a Novel Anti-HER2 Monoclonal Antibody H2Mab-181 for Gastric Cancer
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 168–176, DOI: 10.1089/mab.2021.0021, 2021　(PDF)
262. Kaneko MK, Takei J, Tateyama N, Kato Y.
Epitope Mapping of the Anti-CD44 Monoclonal Antibody (C44Mab-46) Using the REMAP Method
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 156–161, DOI: 10.1089/mab.2021.0012, 2021 (PDF)
261. Sano M, Kaneko MK, Kato Y.
Epitope Mapping of an Anti-human EGFR Monoclonal Antibody (EMab-134) using the REMAP Method
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 191–195, DOI: 10.1089/mab.2021.0014, 2021　(PDF)
260. Tanaka T, Sano M, Takei J, Hosono H, Nanamiya R, Tateyama N, Kaneko MK, Kato Y.
Epitope Mapping of the Anti-California Sea Lion Podoplanin Monoclonal Antibody PMab-269 using Alanine-scanning Mutagenesis and ELISA
Monoclon. Antib. Immunodiagn. Immunother., 40(4), 196–200, DOI: 10.1089/mab.2021.0017, 2021 (PDF)
259. Ohishi T, Takei J, Nakamura T, Nanamiya R, Hosono H, Tanaka T, Sano M, Harada H, Kawada M, Kaneko MK, Kato Y.
Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
Oncol. Rep., 46(2): 173, https://doi.org/10.3892/or.2021.8124, 2021 (PDF)
258. Nanamiya R, Takei J, Sano M, Tanaka T, Hosono H, Harada H, Sakai Y, Mizuno T, Suzuki H, Kaneko MK, Kato Y.
Ferret Podoplanin is Detected by PMab-241 in Immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother.,40(3),134–140, DOI: 10.1089/mab.2021.0016, 2021 (PDF)
257. Nanamiya R, Takei J, Tanaka T, Sano M, Nakamura T, Yanaka M, Hosono H, Kaneko MK, Kato Y.
Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother.,40(3), 101–106, DOI: 10.1089/mab.2021.0007, 2021 (PDF)
256. Hosono H, Takei J, Sano M, Tanaka T, Kaneko MK, Kato Y
Development of an Anti-Elephant Podoplanin Monoclonal Antibody PMab-265 for Flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 40(3), 141–145, DOI: 10.1089/mab.2021.0015, 2021 (PDF)
255. Tanaka T, Sano M, Takei J, Hosono H, Nanamiya R, Nakamura T, Yanaka M, Harada H, Fukui M, Suzuki H, Uchida K, Nakagawa T, Kato Y, Kaneko MK.
Development of Monoclonal Antibody PMab-269 Against California Sea Lion Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 40(3), 124–133, DOI: 10.1089/mab.2021.0011, 2021 (PDF)
254. Nanamiya R, Takei J, Nakamura T, Yanaka M, Hosono H, Tanaka T, Sano M, Kaneko MK, Kato Y.
Development of Anti-Mouse CC Chemokine Receptor 3 Monoclonal Antibodies for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 40(3), 107–112, DOI: 10.1089/mab.2021.0009, 2021 (PDF)
253. Nosaki S, Kaneko MK, Tsuruta F, Yoshida H, Kato Y, Miura K.
Prevention of necrosis caused by transient expression in Nicotiana benthamiana by application of ascorbic acid
Plant Physiol., 186(2), 832–835, https://doi.org/10.1093/plphys/kiab102, 2021 (PDF)
252. Kanayama M, Oyama R, Mori M, Taira A, Shinohara S, Kuwata T, Takenaka M, Yoneda K, Kuroda K, Ohnaga T, Kato Y, Tanaka F.
Novel circulating tumor cell‑detection chip combining conventional podoplanin and EGFR antibodies for all histological malignant pleural mesothelioma
Oncol. Lett., 22(1), 522, https://doi.org/10.3892/ol.2021.12783, 22(1), 522, 2021 (PDF)
251. Tanaka T, Ohishi T, Takei J, Nanamiya R, Hosono H, Sano M, Harada H, Kawada M, Kaneko MK, Kato Y.
An anti-TROP2 monoclonal antibody TrMab-6 exerts antitumor activity in breast cancer mouse xenograft models
Oncol. Rep., 46(1), 132, https://doi.org/10.3892/or.2021.8083, 2021 (PDF)
250. Tamura-Sakaguchi R, Aruga R, Hirose M, Ekimoto T, Miyake T, Hizukuri Y, Oi R, Kaneko M, Kato Y, Akiyama Y, Ikeguchi M, Iwasaki K, Nogi T.
Moving toward generalizable NZ-1 labeling for 3D structure determination with optimized epitope tag insertion
Acta Crystallogr D Struct Biol., 77(Pt 5):645-662, doi: 10.1107/S2059798321002527, 2021　(PDF)
249. Tanaka T, Nanamiya R, Takei J, Nakamura T, Yanaka M, Hosono H, Sano M,Kaneko MK, Kato Y.
Development of Anti-Mouse CC chemokine receptor 8 Monoclonal Antibodies for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother.,40(2), 65–70, DOI: 10.1089/mab.2021.0005, 2021 (PDF)
248. Nanamiya R, Tanaka T, Kaneko MK, Kato Y.
Development of anti-human killer cell lectin-like receptor subfamily G member 1 monoclonal antibodies for flow cytometry
Monoclon. Antib. Immunodiagn. Immunother.,40(2), 76–80, DOI: 10.1089/mab.2021.0008, 2021 (PDF)
247. Takei J, Nanamiya R, Nakamura T, Yanaka M, Hosono H, Tanaka T, Sano M, Kaneko MK, Harada H, Kato Y.
Development of Anti-Human T-Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother.,40(2),71–75, DOI: 10.1089/mab.2021.0006, 2021 (PDF)
246. Sajiki Y, Konnai S, Nagata R, Kawaji S, Nakamura H, Fujisawa S, Okagawa T, Maekawa N, Kato Y, Suzuki Y, Murata S, Mori Y, Ohashi K.
The enhancement of Th1 immune response by anti-PD-L1 antibody in cattle infected with Mycobacterium avium subsp. paratuberculosis
J Vet Med Sci.,83(2),162-166, https://doi.org/10.1292/jvms.20-0590, 2021 (PDF)
245. Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K.
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
NPJ Precis Oncol.,5(1):10;doi: 10.1038/s41698-021-00147-6, 2021　(PDF)
244. Sayama Y, Kaneko MK, Takei J, Hosono H, Sano M, Kato Y.
Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis
Biochem Biophys Rep.,25, 100902, https://doi.org/10.1016/j.bbrep.2020.100902, 2021 (PDF)
243. Sayama Y, Kaneko MK, Kato Y.
Development and characterization of TrMab-6, a novel anti-TROP2 monoclonal antibody for antigen detection in breast cancer
Mol Med Rep. , 23(2),　92, https://doi.org/10.3892/mmr.2020.11731, 2021 (PDF)
242. Sajiki Y, Konnai S, Okagawa T, Maekawa N, Nakamura H, Kato Y, Suzuki Y, Murata S, Ohashi K
A TLR7 agonist activates bovine Th1 response and exerts antiviral activity against bovine leukemia virus
Dev Comp Immunol., 114, 103847, https://doi.org/10.1016/j.dci.2020.103847, 2021 (PDF)

2020

241. Sajiki Y, Konnai S, Cai Z, Takada K, Okagawa T, Maekawa N, Fujisawa S, Kato Y, Suzuki Y, Murata S, Ohashi K.
Enhanced immunotherapeutic efficacy of anti-PD-L1 antibody by combination with EP4 antagonist
ImmunoHorizons, 4 (12) 837-850; DOI: https://doi.org/10.4049/immunohorizons.2000089, 2020 (PDF)
240. Kamoto S, Shinada M, Kato D, Yoshimoto S, Ikeda N, Tsuboi M, Yoshitake R, Eto S, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kaneko MK, Fujita N, Nishimura R, Kato Y, Nakagawa T.
Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma
Cells, 9(11), 2529; https://doi.org/10.3390/cells9112529, 2020 (PDF)
239. Ganbaatar O, Konnai S, Okagawa T, Nojima Y, Maekawa N, Minato E, Kobayashi A, Ando R, Sasaki N, Miyakoshi D, Ichii O, Kato Y, Suzuki Y, Murata S, Ohashi K.
PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
PLoS One, 15(11):e0234218., doi: 10.1371/journal.pone.0234218, 2020 (PDF)
238. Kaneko MK, Ohishi T, Takei J, Sano M, Nakamura T, Hosono H, Yanaka M, Sayama Y, Harada H, Kawada M, Kato Y.*
(*corresponding author)
The Anti-EpCAM monoclonal antibody (EpMab-16) exerts anti-tumor activity against oral squamous cell carcinomas
Oncol Rep., 44(6), 2517-2526, https://doi.org/10.3892/or.2020.7808, 2020 (PDF)
237. Wakasa A, Kaneko MK, Kato Y, Takagi J, Arimori T.
Site-specific epitope insertion into recombinant proteins using the MAP tag system
J Biochem. 168(4), 375–384, mvaa054. doi: 10.1093/jb/mvaa054, 2020 (PDF)
236. Hosono H, Ohishi T, Takei J, Sayama Y, Kawada M, Kaneko MK, Kato Y.*
(*corresponding author)
The anti-EpCAM monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma
Oncol Lett., 20: 383, https://www.spandidos-publications.com/10.3892/ol.2020.12246, 2020 (PDF)
235. Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, Sayama Y, Hosono H, Suzuki H, Kawada M, Kato Y.*
(*corresponding author)
Development of Core-fucose Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies
Monoclon. Antib. Immunodiagn. Immunother., 39(5), 167–174, https://doi.org/10.1089/mab.2020.0019, 2020 (PDF)
234. Ogasawara S, Suzuki K, Naruchi K, Nakamura S, Shimabukuro J, Tsukahara N, Kaneko MK, Kato Y, Murata T.
Crystal structure of an anti-podoplanin antibody bound to a disialylated O-linked glycopeptide
Biochem Biophys Res Commun., 533(1), 57-63, https://doi.org/10.1016/j.bbrc.2020.08.103, 2020 (PDF)
233. Kaneko MK, Ohishi T, Kawada M, Kato Y.
A cancer-specific anti-podocalyxin monoclonal antibody (60-mG2a-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma
Biochem Biophys Rep., 24, 100826, https://doi.org/10.1016/j.bbrep.2020.100826, 2020 (PDF)
232. Takei J, Kaneko MK, Ohishi T, Hosono H, Nakamura T, Yanaka M, Sano M, Sayama Y, Kawada M, Harada H, Kato Y.*
(*corresponding author)
A defucosylated anti-CD44 monoclonal antibody 5-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma
Oncol Rep., 44: 1949-1960, https://doi.org/10.3892/or.2020.7735, 2020 (PDF)
231. Miura K, Yoshida H, Nosaki S, Kaneko MK, Kato Y.
RAP tag and PMab-2 antibody: a tagging system for detecting and purifying proteins in plant cells
Front. Plant Sci.,11, 510444, doi: 10.3389/fpls.2020.510444, 2020 (PDF)
230. Sano M, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope mapping of an anti-diacylglycerol kinase delta monoclonal antibody DdMab-1
Biochem Biophys Rep., 24, 100808, https://doi.org/10.1016/j.bbrep.2020.100808, 2020 (PDF)
229. Takei J, Ohishi T, Kaneko MK, Harada H, Kawada M, Kato Y.*
(*corresponding author)
A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma
Biochem Biophys Rep.,, 24, 100801, https://doi.org/10.1016/j.bbrep.2020.100801, 2020 (PDF)
228. Kaneko MK, Sano M, Takei J, Sayama Y, Hosono H, Kobayashi A, Konnai S, Kato Y.*
(*corresponding author)
Development and Characterization of Anti-Sheep Podoplanin Monoclonal Antibodies PMab-253 and PMab-260
Monoclon. Antib. Immunodiagn. Immunother., 39(4):144–155 DOI: 10.1089/mab.2020.0018, 2020 (PDF)
227. Furusawa Y, Kaneko MK, Kato Y*
(*corresponding author)
Establishment of an Anti-CD20 Monoclonal Antibody (C20Mab-60) for Immunohistochemical Analyses
Monoclon. Antib. Immunodiagn. Immunother.,39(4):112–116, DOI: 10.1089/mab.2020.0015, 2020　(PDF)
226. Kato Y*, Ohishi T, Takei J, Nakamura T, Kawada M, Kaneko MK.
(*corresponding author)
An anti-human epidermal growth factor receptor 2 monoclonal antibody (H2Mab-19) exerts antitumor activity in glioblastoma xenograft models
Monoclon. Antib. Immunodiagn. Immunother.,39(4):135–139, https://doi.org/10.1089/mab.2020.0013, 2020 (PDF)
225. Sano M, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope mapping of DhMab-1, an anti-diacylglycerol kinase monoclonal antibody
Monoclon. Antib. Immunodiagn. Immunother.,39(4):140–143, https://doi.org/10.1089/mab.2020.0014, 2020 (PDF)
224. Kato Y*, Ohishi T, Takei J, Nakamura T, Sano M,Sayama Y, Hosono H, Kawada M, Kaneko MK.
(*corresponding author)
An anti-human epidermal growth factor receptor 2 monoclonal antibody H2Mab-19 exerts antitumor activity in mouse colon cancer xenografts
Monoclon. Antib. Immunodiagn. Immunother.,39(4):123–128, doi:10.1089/mab.2020.0009, 2020 (PDF)
223. Sano M, Takei J, Sayama Y, Kaneko MK, Kato Y*
(*corresponding author)
Epitope mapping of the anti-diacylglycerol kinase monoclonal antibody DhMab-4 for immunohistochemical analysis
Monoclon. Antib. Immunodiagn. Immunother.,39(4):117–122, DOI: 10.1089/mab.2020.0012, 2020 (PDF)
222. Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M.
Anti-metastatic activity of an anti-EGFR monoclonal antibody against metastatic colorectal cancer with KRAS p.G13D mutation.
Int. J. Mol. Sci., 21(17):E6037. doi: 10.3390/ijms21176037, 2020 (PDF)
221. Hosono H, Takei J, Ohishi T, Sano M, Sayama Y, Nakamura T, Yanaka M, Kawada M, Harada H, Kaneko MK, Kato Y*
(*corresponding author)
The anti-EGFR monoclonal antibody 134-mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma
Int J Mol Med, 46(4), 1443-1452, 2020, https://doi.org/10.3892/ijmm.2020.4700 (PDF)
220. Kaneko MK, Kato Y.*
(*corresponding author)
RIEDL tag: A novel pentapeptide tagging system for transmembrane protein purification
Biochem Biophys Rep., 23, 100780; https://doi.org/10.1016/j.bbrep.2020.100780, 2020　(PDF)
219. Mizuno T, Kato Y, Kaneko MK, Sakai Y, Shiga T, Kato M, Tsukui T, Takemoto H, Tokimasa A, Baba K, Nemoto Y, Sakai O, Igase M.
Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment
Sci. Rep., 10, 11476, https://doi.org/10.1038/s41598-020-68470-9, 2020 (PDF)
218. Kato Y*, Sano M, Sayama Y, Kaneko MK.
(*corresponding author)
Thr80 of sheep podoplanin is a critical epitope of the anti-sheep podoplanin monoclonal antibody, PMab-256
Monoclon. Antib. Immunodiagn. Immunother., 39(3):95–100, https://doi.org/10.1089/mab.2020.0010, 2020 (PDF)
217. Kato Y*, Ohishi T, Sano M, Sayama Y, Takei J, Kawada M, Kaneko MK.
(*corresponding author)
H2Mab-19 anti-human epidermal growth factor receptor 2 monoclonal antibody therapy exerts antitumor activity in pancreatic cancer xenograft models
Monoclon. Antib. Immunodiagn. Immunother., 39(3):61–65; , https://doi.org/10.1089/mab.2020.0011, 2020 (PDF)
216. Kato Y*, Takei J, Sano M, Sayama Y, Uchida K, Nakagawa T, Kaneko MK.
(*corresponding author)
Detection of lion podoplanin using the anti-tiger podoplanin monoclonal antibody PMab-231
Monoclon. Antib. Immunodiagn. Immunother.>, 39(3):91–94; , https://doi.org/10.1089/mab.2020.0008, 2020 (PDF)
215. Kato Y*, Furusawa Y, Sano M, Takei J, Nakamura T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Sayama Y, Kaneko MK.
(*corresponding author)
Development of an Anti-Sheep Podoplanin Monoclonal Antibody PMab-256 for Immunohistochemical Analysis of Lymphatic Endothelial Cells
Monoclon. Antib. Immunodiagn. Immunother.>, 39(3):82–90; DOI: 10.1089/mab.2020.0005, 2020 (PDF)
214. Sayama Y, Sano M, Furusawa Y, Takei J, Nakamura T, Yanaka M, Okamoto S, Handa S, Komatsu Y, Nakamura Y, Yanagawa M, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope mapping of PMab-241, a lymphatic endothelial cell-specific anti-bear podoplanin monoclonal antibody
Monoclon. Antib. Immunodiagn. Immunother., 39(3):77–81; DOI: 10.1089/mab.2020.0004, 2020 (PDF)
213. Mukai C, Choi E, Sams KL, Klampen EZ, Anguish L, Marks BA, Rice EJ, Wang Z, Choate LA, Chou SP, Kato Y, Miller AD, Danko CG, Coonrod SA.
Chromatin run-on sequencing analysis finds that ECM remodeling plays an important role in canine hemangiosarcoma pathogenesis 
BMC Vet Res., 16:206, DOI: 10.1186/s12917-020-02395-3, 2020 (PDF)
212. Furusawa Y, Kaneko MK, Kato Y.*
(*corresponding author)
Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells
Oncol Lett., 20(2), 1961-1967; https://doi.org/10.3892/ol.2020.11753, 2020 (PDF; Suppl_Table1)
211. Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, Sajiki Y, Watari K, Minato E, Kobayashi A, Gondaira S, Higuchi H, Koiwa M, Tajima M, Taguchi E, Ishida M, Uemura R, Yamada S, Kaneko M, Kato Y, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K.
Clinical efficacy of the combined treatment of anti-PD-L1 rat-bovine chimeric antibody with a COX-2 inhibitor in calves infected with Mycoplasma bovis
Jpn. J. Vet. Res., 68: 77-90, http://hdl.handle.net/2115/78601, 2020
210. Takei J, Kaneko MK, Ohishi T, Kawada M, Harada H, Kato Y.*
(*corresponding author)
H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts
Exp Ther Med., 20: 846-853, https://doi.org/10.3892/etm.2020.8765, 2020 (PDF); (blog)
209. Akiyama G, Saraswathy S, Bogarin T, Pan X, Barron E, Wong TT, Kaneko MK, Kato Y, Hong Y, Huang AS.
Functional, Structural, and Molecular Identification of Lymphatic Outflow from Subconjunctival Blebs  
Exp Eye Res.,196, 108049, https://doi.org/10.1016/j.exer.2020.108049, 2020 (PDF)
208. Shinada M, Kato D, Kamoto S, Yoshimoto S, Tsuboi M, Yoshitake R, Eto S, Ikeda N, Saeki K, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kaneko MK, Fujita N, Nishimura R, Kato Y, Nakagawa T.
PDPN is expressed in various types of canine tumors and its silencing induces apoptosis and cell cycle arrest in canine malignant melanoma 
Cells, 9(5):E1136. doi: 10.3390/cells9051136., 2020 (PDF)
207. Nishinaga Y, Sato K, Yasui H, Taki S, Takahashi K, Shimizu M, Endo R, Koike C, Kuramoto N, Nakamura S, Fukui T, Yukawa H, Baba Y, K Kaneko M, Chen-Yoshikawa TF, Kobayashi H, Kato Y, Hasegawa Y.
Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
Cells,9(4), 1019; https://doi.org/10.3390/cells9041019, 2020 (PDF)
206. Kato Y*, Ito Y, Ohishi T, Kawada M, Nakamura T, Sayama Y, Sano M, Yanaka M, Okamoto S, Handa S, Komatsu Y, Takei J, Kaneko MK.
(*corresponding author)
Antibody–drug conjugates using mouse–canine chimeric anti-dog podoplanin antibody exerts antitumor activity in a mouse xenograft model
Monoclon. Antib. Immunodiagn. Immunother., 39(2); 37-44; https://doi.org/10.1089/mab.2020.0001, 2020 (PDF)
205. Yamada S, Kaneko MK, Sayama Y, Sano M, Yanaka M, Nakamura T, Okamoto S, Handa S, Komatsu Y, Nakamura Y, Furusawa Y, Takei J, Kato Y.*
(*corresponding author)
Development of novel mouse monoclonal antibodies against human CD19
Monoclon. Antib. Immunodiagn. Immunother., 39(2);45-50; DOI: 10.1089/mab.2020.0003, 2020 (PDF)
204. Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko MK, Kato Y, Tanaka F.
Effective detection of circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM) with the "universal" CTC-chip and an anti-podoplanin antibody NZ-1.2
Cells, 9(4), 888; https://doi.org/10.3390/cells9040888, 2020 (PDF)
203. Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, Kawaji H, Shiozawa K, Machitani M, Abe T, Yamada S, Kaneko MK, Kato Y, Furuta Y, Kondo T, Shirouzu M, Hayashizaki Y, Kaneko S, Masutomi K.
CDK1 dependent phosphorylation of hTERT contributes to cancer progression
Nat Commun.;11(1):1557. doi: 10.1038/s41467-020-15289-7., 2020 (PDF)
202. Sato M, Matsumoto M, Saiki Y, Alam M, Nishizawa H, Rokugo M, Brydun A, Yamada S, Kaneko MK, Funayama R, Ito M, Kato Y, Nakayama K, Unno M, Igarashi K.
BACH1 promotes pancreatic cancer metastasis by repressing epithelial genes and enhancing epithelial-mesenchymal transition
Cancer Res., 80(6):1279-1292.,doi: 10.1158/0008-5472.CAN-18-4099., 2020 (PDF)
201. Takei J, Kaneko MK, Ohishi T, Kawada M, Harada H, Kato Y.*
(*corresponding author)
A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity
Oncol Lett., 19(4), 2809-2816, https://doi.org/10.3892/ol.2020.11384, 2020, (PDF)
200. Goto S, Konnai S, Hirano Y, Kohara J, Okagawa T, Maekawa N, Sajiki Y, Watari K, Minato E, Kobayashi A, Gondaira S, Higuchi H, Koiwa M, Tajima M, Taguchi E, Uemura R, Yamada S, Kaneko M, Kato Y, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K.
Upregulation of PD-L1 expression by prostaglandin E2 and the enhancement of IFN-γ by anti-PD-L1 antibody combined with a COX-2 inhibitor in Mycoplasma bovis infection
Front. Vet. Sci., 7:12. doi: 10.3389/fvets.2020.00012, 2020　(PDF)
199.Sayama Y, Sano M, Kaneko MK, Kato Y*
(*corresponding author)
Epitope analysis of an anti-whale podoplanin monoclonal antibody, PMab-237, using flow cytometry
Monoclon. Antib. Immunodiagn. Immunother., 39(1):17-22, https://doi.org/10.1089/mab.2019.0045, 2020, (PDF)
198.Sano M, Kaneko MK, Suzuki H, Kato Y.*
(*corresponding author)
Establishment and Epitope Mapping of Anti-Diacylglycerol Kinase Alpha Monoclonal Antibody DaMab-8 for immunohistochemical analyses
Monoclon. Antib. Immunodiagn. Immunother., 39(1):1-5, doi: 10.1089/mab.2019.0004.(PDF)

2019

197. Sayama Y, Sano M, Furusawa Y, Kaneko MK, Kato Y*
(*corresponding author)
Epitope Mapping of PMab-225 an Anti-Alpaca Podoplanin Monoclonal Antibody using Flow Cytometry
Monoclon. Antib. Immunodiagn. Immunother., 38(6):255–260, DOI: 10.1089/mab.2019.0033, 2019 (PDF)
196. Takei J, Yamada S, Konnai S, Ishinazaka T, Shimozuru M, Kaneko MK, Kato Y.*
(*corresponding author)
PMab-241 Specifically Detects Bear Podoplanin of Lymphatic endothelial cells in the Lung of Brown Bear
Monoclon. Antib. Immunodiagn. Immunother., 38(6):282–284, https://doi.org/10.1089/mab.2019.0038, 2019 (PDF)
195. Kaneko MK, Sayama Y, Sano M, Kato Y.*
(*corresponding author)
The Epitope of PMab-210 is Located in Platelet Aggregation-Stimulating Domain-3 of Pig Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,38(6):271–276, https://doi.org/10.1089/mab.2019.0037, 2019 (PDF)
194. Kato Y*, Sayama Y, Sano M, Kaneko MK.
(*corresponding author)
Epitope Analysis of an Anti-Horse Podoplanin Monoclonal Antibody PMab-219
Monoclon. Antib. Immunodiagn. Immunother.,38(6):266–270 https://doi.org/10.1089/mab.2019.0034, 2019 (PDF)
193. Sano M, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope Mapping of Monoclonal Antibody PMab-233 Against Tasmanian Devil Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,38(6): 261–265, DOI: 10.1089/mab.2019.0032, 2019 (PDF)
192. Sakamoto S, Inoue H, Kaneko MK, Ogasawara S, Kajikawa M, Urano S, Ohba SI, Kato Y, Kawada M.
Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy
Cancer Sci., 110(11):3595-3602, https://doi.org/10.1111/cas.14196, 2019, (PDF)
191. Kato Y*, Takei J, Furusawa Y, Sayama Y, Sano M, Konnai S, Kobayashi A, Harada H, Takahashi M, Suzuki H, Yamada S, Kaneko MK.
(*corresponding author)
Epitope mapping of anti-bear podoplanin monoclonal antibody PMab-247
Monoclon. Antib. Immunodiagn. Immunother., 38(5): 230–233, https://doi.org/10.1089/mab.2019.0025, 2019 (PDF)
190. Yamada S, Itai S, Furusawa Y, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope mapping of anti-pig podoplanin monoclonal antibody PMab-213
Monoclon. Antib. Immunodiagn. Immunother., 38(5): 224–229, https://doi.org/10.1089/mab.2019.0023, 2019　(PDF)
189. Takei J, Itai S, Harada H, Furusawa Y, Miwa T, Fukui M, Nakamura T, Sano M, Sayama Y, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Yamada S, Kaneko MK, Kato Y.*
(*corresponding author)
Characterization of anti-goat podoplanin monoclonal antibody PMab-235 using immunohistochemistry against goat tissues.
Monoclon. Antib. Immunodiagn. Immunother., 38(5), 213–219, https://doi.org/10.1089/mab.2019.0022, 2019 (PDF)
188. Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, Watari K, Minato E, Kobayashi A, Kohara J, Yamada S, Kaneko MK, Kato Y, Takahashi H, Terasaki N, Takeda A, Yamamoto K, Toda M, Suzuki Y, Murata S, Ohashi K.
Prostaglandin E2–Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti–PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection
J Immunol, 203(5):1313-1324, DOI: https://doi.org/10.4049/jimmunol.1900342, 2019 (PDF)
187. Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Sano M, Sayama Y, Yamada S, Kaneko MK, Kato Y, Goto K.
DzMab-1: Anti-Human Diacylglycerol Kinase-zeta Monoclonal Antibody for Immunocytochemistry.
Monoclon. Antib. Immunodiagn. Immunother., 38(4), 179–182, doi: 10.1089/mab.2019.0020, 2019 (PDF)
186. Sano M, Kaneko MK, Kato Y.*.
(*corresponding author)
Epitope Mapping of Anti-Diacylglycerol Kinase Zeta Monoclonal Antibody DzMab-1 for Immunohistochemical Analyses.
Monoclon. Antib. Immunodiagn. Immunother., 38(4), 175–178, doi: 10.1089/mab.2019.0020, 2019 (PDF)
185. Takei J, Furusawa Y, Yamada S, Nakamura T, Sayama Y, Sano M, Konnai S, Kobayashi A, Harada H, Kaneko MK, Kato Y.*.
(*corresponding author)
PMab-247 Detects Bear Podoplanin in Immunohistochemical Analysis.
Monoclon. Antib. Immunodiagn. Immunother., 38(4), 171–174, https://doi.org/10.1089/mab.2019.0019, 2019 (PDF)
184. Kato Y*, Ohishi T, Yamada S, Itai S, Takei J, Sano M, Nakamura T, Harada H, Kawada M, Kaneko MK.
(*corresponding author)
Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer.
Monoclon. Antib. Immunodiagn. Immunother., 38(4), 157–161; https://doi.org/10.1089/mab.2019.0017, 2019 (PDF)
183. Furusawa Y, Takei J, Sayama Y, Yamada S, Kaneko MK, Kato Y.*
(*corresponding author)
Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis
Biochem Biophys Rep., Volume 18, July 2019, 100644, https://doi.org/10.1016/j.bbrep.2019.100644, 2019 (PDF)
182. Kato Y*, Furusawa Y, Yamada S, Itai S, Takei J, Sano M, Kaneko MK.
(*corresponding author)
Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses
Biochem Biophys Rep., Volume 18, July 2019, 100633, https://authors.elsevier.com/sd/article/S2405580818303194, 2019 (PDF)
181. Furusawa Y, Yamada S, Itai S, Nakamura T, Takei J, Sano M, Harada H, Fukui M, Kaneko MK, Kato Y. *
(*corresponding author)
Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin
Biochem Biophys Rep., Volume 18, July 2019, 100631, https://doi.org/10.1016/j.bbrep.2019.100631 (PDF)
180. Furusawa Y, Yamada S, Nakamura T, Sano M, Sayama Y, Itai S, Takei J, Harada H, Fukui M, Kaneko MK, Kato Y.
PMab-235: a monoclonal antibody for immunohistochemical analysis against goat podoplanin
Heliyon, 5(7), e02063, 2019 (PDF)
179. Jangphattananont N, Sato H, Imamura R, Sakai K, Terakado Y, Murakami K, Barker N, Oshima H, Oshima M, Takagi J, Kato Y, Yano S, Matsumoto K.
Distinct Localization of Mature HGF from its Precursor Form in Developing and Repairing the Stomach
Int. J. Mol. Sci.,20(12), 2955; https://doi.org/10.3390/ijms20122955, 2019 (PDF)
178. Kato Y*, Furusawa Y, Itai S, Takei J, Nakamura T, Sano M, Harada H, Yamada S, Kaneko MK.
(*corresponding author)
Establishment of an anti-cetacean podoplanin monoclonal antibody PMab-237 for immunohistochemical analysis
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 108–113, https://doi.org/10.1089/mab.2019.0013, 2019 (PDF)
177. Yamada S, Itai S, Nakamura T, Takei J, Sano M, Konnai S, Kobayashi A, Nakagun S, Kobayashi Y, Kaneko MK, Kato Y.*
(*corresponding author)
Immunohistochemical analysis of the harbor porpoise using anti-podoplanin antibody PMab-237
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 104–107, https://doi.org/10.1089/mab.2019.0014, 2019 (PDF)
176. Sano M, Kaneko MK, Kato Y.*.
(*corresponding author)
Epitope Mapping of Anti-Human DGKgamma Monoclonal Antibody DgMab-6
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 120–123, https://doi.org/10.1089/mab.2019.0011, 2019 (PDF)
175. Kato Y*, Itai S, Yamada S, Suzuki H, Kaneko MK.
(*corresponding author)
Epitope Mapping of Anti-Diacylglycerol Kinase Zeta Monoclonal Antibody for the Detection of T cells by Immunohistochemical Analyses
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 124–128, doi: 10.1089/mab.2019.0005., 2019 [Epub ahead of print](PDF)
174. Takei J, Itai S, Furusawa Y, Yamada S, Nakamura T, Sano M, Harada H, Fukui M, Kaneko MK, Kato Y*
(*corresponding author)
Epitope mapping of anti-tiger podoplanin monoclonal antibody PMab-231
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 129–132, doi: 10.1089/mab.2019.0012., 2019 (PDF)
173. Kaneko MK, Yamada S, Itai S, Chang YW, Nakamura T, Yanaka M, Harada H, Suzuki H, Kato Y.*
(*corresponding author)
Elucidation of the TMab-6 Monoclonal Antibody Epitope Against Telomerase Reverse Transcriptase
Monoclon. Antib. Immunodiagn. Immunother., 38(3), 101–103, https://doi.org/10.1089/mab.2018.0007, 2019 (PDF)
172. Sakai K, Passioura T, Sato H, Ito K, Furuhashi H, Umitsu M, Takagi J, Kato Y, Mukai H, Warashina S, Zouda M, Watanabe Y, Yano S, Shibata M, Suga H, Matsumoto K.
Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor.
Nat Chem Biol., 15(6):598-606. doi: 10.1038/s41589-019-0285-7, 2019　(PDF)
171. Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, Higashi T.
Therapeutic efficacy evaluation of radioimmunotherapy with 90Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma
Cancer Sci., 110(5):1653-1664, https://doi.org/10.1111/cas.13979, 2019 (PDF)
170. Inoue M, Sakuta N, Watanabe S, Zhang Y, Yoshikaie K, Tanaka Y, Ushioda R, Kato Y, Takagi J, Tsukazaki T, Nagata K, Inaba K.
Structural Basis of Sarco/Endoplasmic Reticulum Ca2+-ATPase 2b Regulation via Transmembrane Helix Interplay
Cell Rep., 27(4):1221-1230.e3. doi: 10.1016/j.celrep.2019.03.106., 2019 (PDF)
169. Kato Y*, Ohishi T, Yamada S, Itai S, Furusawa Y, Sano M, Nakamura T, Kawada M, Kaneko MK.
(*corresponding author)
Anti-CD133 monoclonal antibody CMab-43 exerts antitumor activity in a mouse xenograft model of colon cancer
Monoclon. Antib. Immunodiagn. Immunother., 38(2):75–78, https://doi.org/10.1089/mab.2019.0002, 2019 (PDF)
168. Furusawa Y, Kaneko MK, Nakamura T, Itai S, Fukui M, Harada H, Yamada S, Kato Y.*
(*corresponding author)
Establishment of a monoclonal antibody PMab-231 for tiger podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 38(2):89–95, https://doi.org/10.1089/mab.2019.0003, 2019 (PDF)
167. Kaneko MK, Furusawa Y, Sano M, Itai S, Takei J, Harada H, Fukui M, Yamada S, Kato Y.*
(*corresponding author)
Epitope mapping of the anti-horse podoplanin monoclonal antibody PMab-202
Monoclon. Antib. Immunodiagn. Immunother., 38(2):79–84, https://doi.org/10.1089/mab.2019.0001, 2019 (PDF)
166. Yamada S, Kaneko MK, Furusawa Y, Itai S, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Koyanagi M, Fukui M, Harada H, Kato Y.*
(*corresponding author)
Anti-bovine podoplanin monoclonal antibody PMab-44 detects goat podoplanin in immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., 38(2):96–99, https://doi.org/10.1089/mab.2018.0031, 2019　(PDF)
165. Tamura R, Oi R, Akashi S, Kaneko MK, Kato Y, Nogi T
Application of the NZ-1 Fab as a crystallization chaperone for PA tag-inserted target proteins
Protein Sci. 28(4), 823-836, https://doi.org/10.1002/pro.3580, 2019 (PDF)
164. Kohei Kiname, Sho Yoshimoto, Daiki Kato, Masaya Tsuboi, Yuiko Tanaka, Ryohei Yoshitake, Shotaro Eto, Masahiro Shinada, James Chambers, Kohei Saeki, Ryohei Kinoshita, Shinji Yamada, Kazuyuki Uchida, Mika K. Kaneko, Ryohei Nishimura, Yukinari Kato, Takayuki Nakagawa
Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues
Japanese Journal of Veterinary Research, 67(1); 25-34, 2019 (PDF)
163. Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Fukui M, Harada H, Mizuno T, Sakai Y, Takasu M, Kaneko MK, Kato Y*.
(*corresponding author)
PMab-210: A Monoclonal Antibody Against Pig Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 38(1), 30-36; https://doi.org/10.1089/mab.2018.0038, 2019 (PDF)
162. Sano M, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope Mapping of Anti-Diacylglycerol Kinase alpha Monoclonal Antibody DaMab-2
Monoclon. Antib. Immunodiagn. Immunother., 38(1), 8-11; https://doi.org/10.1089/mab.2018.0047, 2019 (PDF)
161. Kato Y*, Yamada S, Furusawa Y, Itai S, Nakamura T, Yanaka M, Sano M, Harada H, Fukui M, Kaneko MK.
(*corresponding author)
PMab-213: a monoclonal antibody for immunohistochemical analysis against pig podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 38(1), 18-24; https://doi.org/10.1089/mab.2018.0048, 2019 (PDF)
160. Furusawa Y, Yamada S, Itai S, Nakamura T, Yanaka M, Sano M, Harada H, Fukui M, Kaneko MK, Kato Y.*
(*corresponding author)
PMab-219: a monoclonal antibody for the immunohistochemical analysis of horse podoplanin
Biochem Biophys Rep., 18:100616. doi: 10.1016/j.bbrep.2019.01.009., 2019 (PDF)
159. Kato Y*, Ohishi T, Kawada M, Maekawa N, Konnai S, Itai S, Yamada S, Kaneko MK.
(*corresponding author)
The mouse–canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models
Biochem Biophys Rep., 17:23–26, 2019 (PDF)

2018

158. Kato Y*, Yamada S, Itai S, Kobayashi A, Konnai S, Kaneko MK.
(*corresponding author)
Immunohistochemical detection of sheep podoplanin using an anti-bovine podoplanin monoclonal antibody PMab-44
Monoclon. Antib. Immunodiagn. Immunother., 37(6); 265–268, doi: 10.1089/mab.2018.0036., 2018 (PDF)
157. Kato Y*, Yamada S, Itai S, Kobayashi A, Konnai S, Kaneko MK.
(*corresponding author)
Anti-Horse Podoplanin Monoclonal Antibody PMab-219 is useful for detecting lymphatic endothelial cells by immunohistochemical analysis
Monoclon. Antib. Immunodiagn. Immunother., 37(6); 272–274, https://doi.org/10.1089/mab.2018.0044, 2018 (PDF)
156. Kato Y*, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M, Kaneko MK.
(*corresponding author)
Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody against Dog Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,37(5):218–223, https://doi.org/10.1089/mab.2018.0035, 2018　(PDF)
155. Yamada S, Itai S, Furusawa Y, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Fukui M, Harada H, Mizuno T, Sakai Y, Ogasawara S, Murata T, Uchida H, Tahara H, Kaneko MK, Kato Y.*
(*corresponding author)
Detection of tiger podoplanin using the anti-cat podoplanin monoclonal antibody PMab-52
Monoclon. Antib. Immunodiagn. Immunother.,37(5):224–228, https://doi.org/10.1089/mab.2018.0033, 2018　(PDF)
154. Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M, Handa S, Mizuno T, Maeda K, Fukui M, Harada H, Kaneko MK, Kato Y.*
(*corresponding author)
Establishment of Monoclonal Antibody PMab-202 against Horse Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,37(5):233–237, https://doi.org/10.1089/mab.2018.0030, 2018　(PDF)
153. Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Yamaki A, Sakane F, Shirai Y, Nakamura T, Yanaka M, Yamada S, Kaneko MK, Kato Y, Goto K.
DgMab-6: Anti-Human DGKgamma Monoclonal Antibody for immunocytochemistry
Monoclon. Antib. Immunodiagn. Immunother.,37(5):233–237, https://doi.org/10.1089/mab.2018.0026, 2018　(PDF)
152. Itai S, Yamada S, Kaneko MK, Sano M, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Furusawa Y, Fukui M, Ohishi T, Kawada M, Harada H, Kato Y.*.
(*corresponding author)
Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2
Biochem Biophys Rep., 15: 93-96, https://doi.org/10.1016/j.bbrep.2018.07.008, 2018　(PDF)
151. Furusawa Y, Yamada S, Itai S, Nakamura T, Fukui M, Harada H, Kaneko MK, Kato Y.*
(*corresponding author)
Elucidation of critical epitope of anti-rat podoplanin monoclonal antibody PMab-2
Monoclon. Antib. Immunodiagn. Immunother., 37(4): 188–193, https://doi.org/10.1089/mab.2018.0025, 2018 (PDF)
150. Kaneko MK, Yamada S, Itai S, Furusawa Y, Nakamura T, Yanaka M, Handa S, Hisamatsu K, Nakamura Y, Fukui M, Harada H, Kato Y*.
(*corresponding author)
Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6
Biochem Biophys Rep.,15: 76-80, https://doi.org/10.1016/j.bbrep.2018.07.003, 2018 (PDF)
149. Yamada S, Itai S, Kaneko MK, Konnai S, Kato Y*.
(*corresponding author)
Epitope mapping of anti-mouse podoplanin monoclonal antibody PMab-1
Biochem Biophys Rep., 15:52-56, https://doi.org/10.1016/j.bbrep.2018.07.002, 2018 (PDF)
148. Furusawa Y, Itai S, Yamada S, Kaneko MK, Kato Y.*
(*corresponding author)
Epitope mapping of anti-telomerase reverse transcriptase (TERT) monoclonal antibodies
Monoclon. Antib. Immunodiagn. Immunother., 37(4): 185–187, https://doi.org/10.1089/mab.2018.0019, 2018 (PDF)
147. Okagawa T, Konnai S, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Kohara J, Suzuki Y, Yamada S, Kato Y, Murata S, Ohashi K.
Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection
Vet Res.,49(1):50. doi: 10.1186/s13567-018-0543-9., 2018 (PDF)
146. Itai S, Yamada S, Kaneko MK, Kato Y*.
(*corresponding author)
Determination of critical epitope of PcMab-47 against human podocalyxin
Biochem Biophys Rep.,14: 78–82, https://doi.org/10.1016/j.bbrep.2018.04.003, 2018 (PDF)
145. Kaneko MK, Yamada S, Itai S, Chang YW, Nakamura T, Yanaka M, Kato Y*.
(*corresponding author)
Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
Biochem Biophys Rep., 14, 54-57, 2018 (PDF)
144. Yamada Y, Itai S, Nakamura T, Yanaka M, Kaneko MK, Kato Y*.
(*corresponding author)
Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5
Biochem Biophys Rep.,14, 64-68, 2018 (PDF)
143. Kato Y*, Yamada S, Itai S, Konnai S, Kobayashi A, Kaneko MK.
(*corresponding author)
Detection of alpaca podoplanin by immunohistochemistry using the anti-bovine podoplanin monoclonal antibody PMab-44
Monoclon. Antib. Immunodiagn. Immunother., 37(6); 269–271, doi: 10.1089/mab.2018.0037, 2018(PDF)
142. Itai S, Ohishi T, Kaneko MK, Yamada S, Abe S, Nakamura T, Yanaka M, Chang YW, Ohba SI, Nishioka Y, Kawada M, Harada H, Kato Y*.
(*corresponding author)
Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
Oncotarget, 9(32):22480-22497, https://doi.org/10.18632/oncotarget.25132, 2018 (PDF)
141. Tabata S, Kitago Y, Fujii Y, Mihara E, Tamura-Kawakami K, Norioka N, Takahashi K, Kaneko MK, Kato Y, Takagi J.
An anti-peptide monoclonal antibody recognizing the tobacco etch virus protease-cleavage sequence and its application to a tandem tagging system.
Protein Expr Purif., 147, 94-99, doi: 10.1016/j.pep.2018.03.004, 2018 (PDF)
140. Kaneko MK, Itai S, Yamada S, Kato Y*.
(*corresponding author)
47-mG2a: A Mouse IgG2a-type of PcMab-47 Useful for Detecting Podocalyxin in Esophageal Cancers by Immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother., doi: 10.1089/mab.2018.0003., 37(3),158–161, 2018 (PDF)
139. Miyazaki A, Nakai H, Sonoda T, Hirohashi Y, Kaneko MK, Kato Y, Sawa Y, Hiratsuka H.
LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of oral cancer.
Oncotarget,9(30):21156-21165. https://doi.org/10.18632/oncotarget.24986, 2018 (PDF)
138. Yamada S, Itai S, Nakamura T, Yanaka M, Chang YW, Suzuki H, Kaneko MK, Kato Y.*.
(*corresponding author)
Monoclonal Antibody L1Mab-13 Detected PD-L1 in Lung Cancers.
Monoclon. Antib. Immunodiagn. Immunother., doi: 10.1089/mab.2018.0004, , 37(2), 110-115, 2018 (PDF)
137. Yamada S, Kaneko MK, Itai S, Chang YW, Nakamura T, Yanaka M, Ogasawara S, Murata T, Uchida H, Tahara H, Harada H, Kato Y.*.
(*corresponding author)
Epitope Mapping of Monoclonal Antibody PMab-48 against Dog Podoplanin.
Monoclon. Antib. Immunodiagn. Immunother., doi: 10.1089/mab.2018.0006, 37(3),162–165, 2018 (PDF)
136. Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A.
Immunohistochemical ATRX loss cannot be a surrogate for 1p19q codeletion.
Brain Tumor Pathol., doi: 10.1007/s10014-018-0312-5., 2018 (PDF)
135. Ito A, Ohta M, Kato Y, Inada S, Kato T, Nakata S, Yatabe Y, Goto M, Kaneda N, Kurita K, Nakanishi H, Yoshida K.
A real time near-infrared imaging method for the detection of oral cancers in mice using an indocyanine green-labeled podoplanin antibody.
Technol Cancer Res Treat., 17:1533033818767936. doi: 10.1177/1533033818767936., 2018 (PDF）
134. Sajiki Y, Konnai S, Okagawa T, Nishimori A, Maekawa N, Goto S, Ikebuchi R, Nagata R, Kawaji S, Kagawa Y, Yamada S, Kato Y, Nakajima C, Suzuki Y, Murata S, Mori Y, Ohashi K.
Prostaglandin E2 induction suppresses the Th1 immune responses in cattle with Johne's disease.
Infect Immun., 2018 Feb 26. pii: IAI.00910-17. doi: 10.1128/IAI.00910-17. (PDF）
133. Yamada S, Itai S, Kaneko MK, Kato Y*.
(*corresponding author)
Anti-Podocalyxin Monoclonal Antibody 47-mG2a Detects Lung Cancers by Immunohistochemistry Analyses.
Monoclon. Antib. Immunodiagn. Immunother., 37(2), https://doi.org/10.1089/mab.2018.0002, 91-94, 2018 (PDF)
132. Yamada S, Itai S, Kaneko MK, Kato Y*.
(*corresponding author)
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Biochem Biophys Rep., 13, 123–128, 2018 (PDF)
131. Retzbach EP, Sheehan SA, Nevel E, Batra A, Phi T, Kato Y, Baredes S, Fatahzadeh M, Shienbaum AJ, and Goldberg GS.
Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
Oral Oncology, 78, 126–136, 2018 (PDF)
130. Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, Kaneko MK, Oki H, Suzuki H, Nitta M, Maruyama T, Muragaki Y, Kawamata T, Sawada T, Shibata N.
Elevated TERT Expression in TERT Wild-Type Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody
Biomed Res Int.:7945845. doi: 10.1155/2018/7945845., 2018 (PDF)
129. Chang YW, Kaneko MK, Yamada S, Kato Y.*
(*corresponding author)
Epitope Mapping of Monoclonal Antibody PMab-52 Against Cat Podoplanin.
Monoclon. Antib. Immunodiagn. Immunother., https://doi.org/10.1089/mab.2017.0067, 37(2): 95–99, 2018 (PDF)
128. Kaneko MK, Yamada, S, Itai S, Kato Y*.
(*corresponding author)
Development of an Anti-HER2 Monoclonal Antibody (H2Mab-139) Against Colon Cancer.
Monoclon. Antib. Immunodiagn. Immunother., 37(1): 59-62, 2018 (PDF)
127. Suzuki T, Takakubo Y, Oki H, Liu X, Honma R, Naganuma Y, Goodman S, Kaneko MK, Kato Y, Takagi M.
Immunohistochemical Analysis of Inflammatory Rheumatoid Synovial Tissues Using Anti-Human Podoplanin Monoclonal Antibody Panel.
Monoclon. Antib. Immunodiagn. Immunother., 37(1): 12-19, 2018 (PDF)
126. Yamada S, Itai S, Kaneko MK, Kato Y*.
(*corresponding author)
PMab-48 recognizes canine podoplanin of lymphatic endothelial cells.
Monoclon. Antib. Immunodiagn. Immunother., 37(1): 63-66, 2018 (PDF)

2017

125. Yamada S, Itai S, Nakamura T, Chang YW, Harada H, Suzuki H, Kaneko MK, Kato Y*.
(*corresponding author)
Establishment of H2Mab-119, an Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody, Against Pancreatic Cancer.
Monoclon. Antib. Immunodiagn. Immunother.,36(6): 287-290, 2017 (PDF)
124. Chang YW, Yamada S, Kaneko MK, Kato Y*.
(*corresponding author)
Epitope Mapping of Monoclonal Antibody PMab-38 Against Dog Podoplanin.
Monoclon. Antib. Immunodiagn. Immunother., 36(6): 291-295, 2017 (PDF)
123. Tamahara T, Ochiai K, Muto A, Kato Y, Sax N, Matsumoto M, Koseki T, Igarashi K.
mTOR-Bach2 cascade controls cell cycle and class switch recombination during B cell differentiation.
Mol Cell Biol., 37(24). pii: e00418-17, 2017
122. Itai S, Yamada S, Kaneko MK, Harada H, Kagawa Y, Konnai S, Kato Y*.
(*corresponding author)
Expression of cat podoplanin in feline squamous cell carcinomas.
Monoclon. Antib. Immunodiagn. Immunother.,36(6): 243-250, 2017 (PDF)
121. Itai S, Yamada S, Kaneko MK, Chang YW, Harada, H, Kato Y*.
(*corresponding author)
Establishment of EMab-134, a sensitive and specific anti-epidermal growth factor receptor monoclonal antibody for detecting squamous cell carcinoma cells of the oral cavity.
Monoclon. Antib. Immunodiagn. Immunother., 36(6): 272-281, 2017 (PDF)
120. Itai S, Fujii Y, Nakamura T, Chang YW, Yanaka M, Saidoh N, Handa S, Suzuki H, Harada H, Yamada S, Kaneko MK, Kato Y.
(*corresponding author)
Establishment of CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for Immunohistochemistry.
Monoclon. Antib. Immunodiagn. Immunother., 36(5): 231-235, 2017　(PDF)
PDIS
119. Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, Kato Y, Yamamoto K, Uemura H, Suzuki Y, Murata S, Ohashi K.
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Sci Rep. ,7(1):8951. doi: 10.1038/s41598-017-09444-2, 2017
PDIS
118. Itai S, Kaneko MK, Fujii Y, Yamada S, Nakamura T, Yanaka M, Saidoh N, Handa S, Chang YW, Suzuki H, Harada H, Kato Y.
(*corresponding author)
Development of EMab-51, a Sensitive and Specific Anti-EGFR Monoclonal Antibody in Western Blot and Immunohistochemistry.
Monoclon. Antib. Immunodiagn. Immunother., 36(5): 214-219, 2017 (PDF)
PDIS
117. Itai S, Yamada S, Kaneko MK, Harada H, Kato Y.
(*corresponding author)
Immunohistochemical Analysis Using Anti-Podocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinoma Cells.
Monoclon. Antib. Immunodiagn. Immunother., 36(5): 220-223, 2017 (PDF)
PDIS
116. Jung E, Gardner D, Choi D, Park E, Jin Seong Y, Yang S, Castorena-Gonzalez J, Louveau A, Zhou Z, Lee GK, Perrault DP, Lee S, Johnson M, Daghlian G, Lee M, Jin Hong Y, Kato Y, Kipnis J, Davis MJ, Wong AK, Hong YK.
Development and Characterization of A Novel Prox1-EGFP Lymphatic and Schlemm's Canal Reporter Rat.
Open Access
Sci Rep., 7(1):5577. doi: 10.1038/s41598-017-06031-3., 2017 (PDF)
PDIS
115. Yamada S, Itai S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Harada H, Kagawa Y, Ichii O, Konnai S, Kaneko MK, Kato Y*.
(*corresponding author)
PMab-52: Specific and Sensitive Monoclonal Antibody against Cat Podoplanin for Immunohistochemistry.
Monoclon. Antib. Immunodiagn. Immunother., 36(5): 224-230, 2017 (PDF)
PDIS
114. Itai S, Fujii Y, Kaneko MK, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Takahashi M, Suzuki H, Harada H, Kato Y*.
(*corresponding author)
H2Mab-77 is a sensitive and specific anti-HER2 monoclonal antibody against breast cancer.
Monoclon. Antib. Immunodiagn. Immunother.,36(4): 143-148, 2017 (PDF)
PDIS
113. Okagawa T, Konnai S, Nishimori A, Maekawa N, Ikebuchi R, Goto S, Nakajima C, Kohara J, Ogasawara S, Kato Y, Suzuki Y, Murata S, and Ohashi K.
Open Access
Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.
Frontiers in Immunology;8:650. doi: 10.3389/fimmu.2017.00650, 2017. (PDF)
PDIS
112. Nakano T, Ogasawara S, Tanaka T, Hozumi Y, Mizuno S, Satoh E, Sakane F, Okada N, Taketomi A, Honma R, Nakamura T, Saidoh N, Yanaka M, Itai S, Handa S, Chang YW, Yamada S, Kaneko MK, Kato Y, Goto K.
DaMab-2: Anti-Human DGK Monoclonal Antibody for immunocytochemistry.
Monoclon. Antib. Immunodiagn. Immunother., 36(4): 181-184, 2017 (PDF)
PDIS
111. Goto S, Konnai S, Okagawa T, Nishimori A, Maekawa N, Gondaira S, Higuchi H, Koiwa M, Tajima M, Kohara J, Ogasawara S, Kato Y, Suzuki Y, Murata S, Ohashi K.
Increase of cells expressing PD-1 and PD-L1 and enhancement of IFN-γ production via PD-1/PD-L1 blockade in bovine mycoplasmosis.
Open Access
Immun Inflamm Dis. 2017 May 24. doi: 10.1002/iid3.173. (PDF)
PDIS
110. Nuemket N, Yasui N, Kusakabe Y, Nomura Y, Atsumi N, Akiyama S, Nango E, Kato Y, Kaneko MK, Takagi J, Hosotani M, Yamashita A.
Structural basis for perception of diverse chemical substances by T1r taste receptors.
Open Access
Nature Communications, 23;8:15530, 2017 (PDF)
PDIS
109. Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y.*
(*corresponding author)
Anti-Podocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
Monoclon. Antib. Immunodiagn. Immunother., 36(4): 157-162, 2017(PDF)
PDIS
108. Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K.
In vitro and in vivo antivirus activity of an antiprogrammed death-ligand 1 (PD-L1) ratbovine chimeric antibody against bovine leukemia virus infection.
Open Access
PLoS ONE, 12(4): e0174916., 2017 (PDF)
PDIS
107. Yamada S, Honma R, Kaneko MK, Nakamura T, Yanaka M, Saidoh N, Takagi M, Konnai S, Kato Y.*
(*corresponding author)
Characterization of Anti-bovine Podoplanin Monoclonal Antibody PMab-44
Monoclon. Antib. Immunodiagn. Immunother., 36(3): 129-134, 2017 (PDF)
PDIS
106. Shirakabe K, Omura T, Shibagaki Y, Mihara E, Homma K, Kato Y, Yoshimura A, Murakami Y, Takagi J, Hattori S, Ogawa Y.
Mechanistic insights into ectodomain shedding: susceptibility of CADM1 adhesion molecule is determined by alternative splicing and O-glycosylation.
Open Access
Sci Rep., 7:46174, doi: 10.1038/srep46174, 2017 (PDF)
PDIS
105. Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.*
(*corresponding author)
ChLpMab-23: Cancer-specific Human–Mouse Chimeric Anti-podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity
Monoclon. Antib. Immunodiagn. Immunother., 36(3): 104-112, 2017 (PDF)
PDIS
104. Ogasawara S, Kaneko MK, Yamada S, Honma R, Nakamura T, Saidoh N, Yanaka M, Yoshida K, Fujii Y, Kato Y.*
(*corresponding author)
PcMab-47: Novel Anti-human Podocalyxin Monoclonal Antibody for Immunohistochemistry
Open Access
Monoclon. Antib. Immunodiagn. Immunother., 36(2): 50-56, 2017(PDF)
PDIS
103. Yamada S, Ogasawara S, Kaneko MK, Kato Y.*
(*corresponding author)
LpMab-23: A Cancer-Specific Monoclonal Antibody against Human Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 36(2): 72-76, 2017 (PDF)
PDIS
102. Yamada S, Kaneko MK, Nakamura T, Ichii O, Konnai S, Kato Y.*
(*corresponding author)
Development of mPMab-1, a Mouse-Rat Chimeric Antibody against Mouse Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,36(2): 77-79, 2017 (PDF)
PDIS
101．Ohka F,Yamamichi A, Kurimoto M, Motomura K, Tanahashi K, Suzuki H, Aoki K, Deguchi S, Chalise L, Hirano M, Kato A, Nishimura Y, Hara M, Kato Y, Wakabayashi T, Natsume A.
A Novel All-in-one Intraoperative Genotyping System for IDH1-mutant Glioma
Brain Tumor Pathol., 34(2):91-97., 2017
100. Fujii Y, Kaneko MK, Ogasawara S, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Honma R, Kato Y.
(*corresponding author)
Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification
Open Access
Monoclon. Antib. Immunodiagn. Immunother., 36(2): 68-71, 2017 (PDF)
PDIS
99. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y*
(*corresponding author)
Antitumor activity of chLpMab-2, a human–mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity
Open Access
Cancer Med., 6(4): 768-777, 2017 (PDF)
PDIS
98. Kato Y*, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK*
(*corresponding author)
Anti-Glycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
Monoclon. Antib. Immunodiagn. Immunother., 36(1): 20-24, 2017 (PDF)
PDIS
97．Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y*.
(*corresponding author)
Chimeric Anti-human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain
Monoclon. Antib. Immunodiagn. Immunother., 36(1): 25-29, 2017 (PDF)
PDIS
96．Takara K, Maruo N, Oka K, Kaji C, Hatakeyama Y, Sawa N, Kato Y, Yamashita J, Kojima H, Sawa Y.
Morphological study of tooth development in podoplanin-deficient mice
Open Access
PLoS One., PLoS One. 2017 Feb 21;12(2):e0171912. (PDF)
95．Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y*.
(*corresponding author)
Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN
Open Access
Cancer Med., 6(2); 382–396, 2017 (PDF)
PDIS

2016

94．Ogasawara S, Honma R, Kaneko MK, Fujii Y, Kagawa Y, Konnai S, Kato Y*
(*corresponding author)
Podoplanin Expression in Canine Melanoma
Open Access
Monoclon. Antib. Immunodiagn. Immunother., 35(6): 304-306, 2016 (PDF)
PDIS
93. Fujii Y, Kaneko MK, Kato Y*.
(*corresponding author)
MAP tag: A novel tagging system for protein purification and detection.
Open Access
Monoclon. Antib. Immunodiagn. Immunother., 35(6): 293-299, 2016 (PDF)
PDIS
92．Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y*.
(*corresponding author)
Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Open Access
Monoclon. Antib. Immunodiagn. Immunother., 35(5): 254-258, 2016 (PDF)
PDIS
91．Kaneko MK, Honma R, Ogasawara S, Fujii Y, Nakamura T, Saidoh N, Takagi M, Kagawa Y, Konnai S, Kato Y*.
(*corresponding author)
PMab-38 recognizes canine podoplanin of squamous cell carcinomas.
Monoclon. Antib. Immunodiagn. Immunother., 35(5): 263-266, 2016 (PDF)
PDIS
90. Ogasawara S, Kaneko MK, Kato Y*
(*corresponding author)
LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,35(5): 245-253, 2016 (PDF)
PDIS
89．Hayashi A, Misumi K, Shibahara J, Kokudo N, Kato Y and Fukayama M.

Immunohistochemistry Using Monoclonal Antibody MsMab-2 Is Useful to Detect IDH1 R132L in Intrahepatic Cholangiocarcinoma.
Pathology international, 66(10); 578–582, 2016 (PDF)
PDIS
88．Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto K, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Wakabayashi T, Baba Y, Kato Y, Natsume A.
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas
Sci Technol Adv Mater.,17; 618-625, 2016 (PDF)
PDIS
87．Kitago Y, Kaneko MK, Ogasawara S, Kato Y*, Takagia J*.
(*corresponding author)
Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1
Biochemical and Biophysical Research Communications, 478(3):1274-9., 2016 (PDF)
PDIS
86. Umitsu M, Sakai K, Ogasawara S, Kaneko MK, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J.
Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies
Open Access
Scientific Reports,6, Article number: 33149 (PDF)
PDIS
85．Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, Kato Y*
(*corresponding author)
Specific Detection of Dog Podoplanin Expressed in Renal Glomerulus by A Novel Monoclonal Antibody PMab-38 in Immunohistochemistry.
Monoclon. Antib. Immunodiagn. Immunother.,35(4): 212-216, 2016 (PDF)
PDIS
84．Honma R, Ogasawara S, Kaneko MK, Fujii Y, Oki H, Nakamura T, Takagi M, Konnai S, Kato Y * (*corresponding author)
PMab-44 Detects Bovine Podoplanin in Immunohistochemistry
Monoclon. Antib. Immunodiagn. Immunother.,35(4): 186-190, 2016(PDF)
PDIS
83．Kato Y*, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK.
(*corresponding author)
LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin
Open Access
PLoS ONE,11(3): e0152912., 2016 (PDF)
PDIS
82． Kato Y*, Ogasawara S, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK.
(*corresponding author)
Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 35(2): 109-116, 2016 (PDF)
PDIS
81. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y*
(*corresponding author)
Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin
Monoclon. Antib. Immunodiagn. Immunother.,35(3):155-162, 2016(PDF)
PDIS
80．Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J.
Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state
J Cell Sci,,29(7):1512-22, 2016 (PDF)
PDIS
79．Honma R, Fujii Y, Ogasawara S, Oki H, Konnai S, Kagawa Y, Takagi M, Kaneko MK, Kato Y * (*corresponding author)
Critical Epitope of Anti-Rabbit Podoplanin Monoclonal Antibodies for Immunohistochemical Analysis
Monoclon. Antib. Immunodiagn. Immunother., 35(2): 65-72, 2016(PDF)
PDIS
78．Honma R, Fujii Y, Ogasawara S, Oki H, Liu X, Nakamura T, Kaneko MK, Takagi M, Kato Y* (*corresponding author)
Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin
Monoclon. Antib. Immunodiagn. Immunother., 35(1): 41-47, 2016 (PDF)
PDIS
77．Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Okada N, Miyamoto R, Sato C, Tobiume M, Otsuka K, Tsuchiya K, Kawazoe K, Ogasawara S, Kato Y, and Nishioka Y.
Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in orthotopic xenograft model
Open Access
Cancer Sci.,107, 1198–1205, 2016(PDF)
PDIS
76．Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T, Matsumura A.
Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas
Brain Tumor Pathol.,33(2):107-116, 2016 (PDF)
75．Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.
CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains
Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
PDIS
74．Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, Kato Y, Murata S, Ohashi K.
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers
Open Access
PLoS ONE; 11(6):e0157176, 2016 (PDF)
PDIS

2015

73．Kato Y*, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, and Kaneko MK.
(*corresponding author)

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.

Oncotarget, 6(34): 36003-36018, 2015 (PDF)
PDIS
72．Kato Y.*
(*corresponding author)

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

Brain Tumor Pathol.,32(1): 3-11, 2015
PDIS
71． Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y*
(*corresponding author)

A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin.

Monoclon. Antib. Immunodiagn. Immunother.,34(5): 310-317, 2015 (PDF)
PDIS
70．Kaneko MK, Oki H, Ogasawara S, Takagi M, Kato Y*
(*corresponding author)

An anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of osteosarcoma

Monoclon. Antib. Immunodiagn. Immunother., 34(3): 154-161, 2015 (PDF)
PDIS
69．Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*
(*corresponding author)

Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin.

Monoclon. Antib. Immunodiagn. Immunother., 34(5): 318-326, 2015 (PDF)
PDIS
68．Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y*
(*corresponding author)

A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas

Biochem Biophys Res Commun., 466(4),733–739, 2015 (PDF)
PDIS
67．Oki H, Honma R, Ogasawara S, Fujii Y, Liu X, Kaneko MK, Takagi M, Kato Y*
(*corresponding author)

Development of a sensitive monoclonal antibody PMab-2 against rat podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 34(6): 396-403, 2015 (PDF)
PDIS
66．Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y*
(*corresponding author)

Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 34(3): 174-180, 2015 (PDF)
PDIS
65．Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi Y, Kato Y.*
(*corresponding author)

Characterization of a monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.

Monoclon. Antib. Immunodiagn. Immunother.,34(1): 44-50, 2015
PDIS
64．Liu X, Ogasawara S, Kaneko MK, Oki H, Hozumi Y, Goto K, Takagi M, Kato Y.*
(*corresponding author)

A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma

Biochem Biophys Res Commun., 459(4),636–642, 2015 (PDF)
PDIS
63．Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Yin K, Shienbaum AJ, Jensen LD, and Goldberg GS.

Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

Oncotarget,6(11),9045-9060,2015
PDIS
62．Ikota H, Nobusawa S, Arai H, Kato Y, Ishizawa K, Hirose T, Yokoo H.

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies

Brain Tumor Pathol., 32(4):237-44, 2015
PDIS
61．Takano S, Kato Y, Yamamoto T, Liu X, Ishikawa E, Kaneko MK, Ogasawara S, Matsuda M, Noguchi M, Matsumura A.

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.

Brain Tumor Pathol., July 2015, Volume 32, Issue 3, pp 169-175
PDIS

2014

60．Kato Y* and Kaneko MK.
(*corresponding author)

A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin.

Sci Rep 4, 5924, 2014（@東北大学）（注目の論文）
PDIS
59．Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.*
(*corresponding author)
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone
Cancer Sci.,105(6),744-8,2014　(pdf)（医化学、山形大学整形外科との共同研究@東北大学）PDIS
58．Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y*, Takagi J*
(*corresponding author)

PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin.

Protein Expr Purif. Volume 95, 240-247, 2014 (pdf)（大阪大学との共同研究@東北大学）PDIS
57．Moriya K, Kaneko MK, Liu X, Hosaka M, Fujishima F, Watanabe M, Ogasawara S, Sakuma J, Sasahara Y, Kure S, Kato Y*
(*corresponding author)

IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome.

Cancer Sci., 105(3),359-362,2014（小児科、整形外科との共同研究@東北大学）PDIS
56．Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y.

A novel platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and non-glycosylated rhodocytin.

Structure, Volume 22, Issue 12, p1711–1721, 2 December 2014 （理研との共同研究@東北大学）
PDIS
55．Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutaion

Tumor Biol., 35(6):5911-20（名古屋大学、慶応大学先端研との共同研究@東北大学）PDIS
54．Maruyama Y, Maruyama K, Kato Y, Kajiya K, Moritoh S, Yamamoto K, Matsumoto Y, Kerjaschki D, Nakazawa T, Kinoshita S.

The Effect of Podoplanin Inhibition on Lymphangiogenesis under Pathological Conditions.

Invest Ophthalmol Vis Sci., 55:4813-4822; 2014（眼科との共同研究@東北大学）PDIS
53．Sabit H, Nakada M, Furuta T, Watanabe T, Hayashi Y, Sato H, Kato Y, Hamada JI.

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence

Brain Tumor Pathol., Oct;31(4):242-6. (pdf)（金沢大学との共同研究@東北大学）

2013

52．Kato Y* and Kaneko MK.
(*corresponding author)

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation

Biochem Biophys Res Commun., 433(4), 374?378, 2013 (pdf)（@山形大学）PDIS
51．Kato Y*, Natsume A, Kaneko MK.
(*corresponding author)

A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation

Biochem Biophys Res Commun., 432(4):564-7, 2013 (pdf)（名古屋大学との共同研究@山形大学）PDIS
50．Kaneko MK, Ogasawara S, Kato Y*.
(*corresponding author)

Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.

TJEM, 230: 103-109, 2013（@東北大学）PDIS
49．Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y*.
(*corresponding author)

Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations

Monoclon. Antib. Immunodiagn. Immunother., 32(3), 224-228, 2013 (PDF)（山形大学解剖学との共同研究@山形大学）PDIS
48．Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y*
(*corresponding author)

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations

Biochem Biophys Res Commun., 432(1):40-5, 2013 (PDF)（東北大学、名古屋大学との共同研究@山形大学）PDIS
47．Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y*.
(*corresponding author)

A Multi-specific Monoclonal Antibody MsMab-2 Recognizes IDH1-R132L and IDH2-R172M Mutations.

Monoclon. Antib. Immunodiagn. Immunother., 32(6), 377-381, 2013 (pdf)（@東北大学）PDIS
46．Liu X, Kato Y*, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.
(*corresponding author)

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Cancer Med.,2(6): 803?814, 2013 (PDF)（山形大学整形外科との共同研究@東北大学）PDIS
45．Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

J. Immunol., 190(12):6239-49 (pdf)（徳島大学との共同研究@山形大学）PDIS
44．Chandramohan V, Bao X, Kaneko MK, Kato Y, Keir ST, Szafranski S, Kuan CT, Pastan I, Bigner DD.

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

Int. J. Cancer;132(10):2339-48, 2013 (pdf)（@Duke大学）
43．Yoshikawa A, Nakada M, Watanabe T, Hayashi Y, Sabit H, Kato Y, Suzuki S, Ooi A, Sato H, Hamada JI.

Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.

Brain Tumor Pathol., 30(3):175-9, 2013 (pdf)（金沢大学との共同研究@山形大学）

2012

42．Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y*.
(*corresponding author)

Chimeric anti-podoplanin antibody suppresses tumor metastasis via neutralization and antibody-dependent cellular cytotoxicity

Cancer Sci., 103 (11), 1913?1919, 2012 (pdf)（東京大学との共同研究@山形大学）
41．Chiaki Kaji, Yuta Tsujimoto, Mika Kato Kaneko, Yukinari Kato*, and Yoshihiko Sawa*.
(*corresponding author)

Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin.

Acta Histochm. Cytochem., 45 (4): 227-237, 2012 (pdf)（福岡歯科大学との共同研究@山形大学）
40．Takano S, Kato Y*, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.
(*corresponding author)

Immunohistochemical detection of IDH1 mutation, p53 and internexin as a prognostic factor of glial tumors

J Neurooncol. 2012 Jul;108(3):361-73（筑波大学との共同研究@山形大学）
39．Hatakeyama K, Kaneko MK, Kato Y*, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y.
(*corresponding author)

Podoplanin expression in advanced atherosclerotic lesions of human aortas

Thromb. Res. 129: 70-76, 2012 (pdf)（宮崎大学との共同研究@山形大学）
38．Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price JE.

The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model.

BMC Cancer.;12(1):583. [Epub ahead of print], on line (pdf)（@MDアンダーソン癌センター）
37．Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayash T.

Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas with integrated genomic and epigenetic profiles

Cancer Sci.,103(10):1871-9., 2012 (pdf)（名古屋大学との共同研究@山形大学）
36．Kaji C, Tomooka M, Kato Y, Kojima H, Sawa Y

The expression of podoplanin and classical cadherins in the brain

J Anat. ;220(5):435-46, 2012 (pdf)（福岡歯科大学との共同研究@山形大学） DOI: 10.1111/j.1469-7580.2012.01484.x
35．Kwon MJ, Kim ST, Kwon MJ, Kong DS, Lee D, Park S, Kang SY, Song JY, Nam DH, Kato Y, Choi YL, Suh YL.

IDH1 mutation is a favorable prognostic factor for type 2 gliomatosis cerebri

Brain Pathol. ;22(3):307-317, 2012（韓国との共同研究@山形大学）

2011

34．Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kato Y*(*corresponding author)

Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation.

Biochem Biophys Res Commun., 406(4), 608-613,2011 (pdf)（山形大学法医学との共同研究@山形大学）
33．Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

Brain Tumor Pathology., 28(2), 115-123, 2011 (pdf)（筑波大学との共同研究@山形大学）

2010

32．Kato Y*, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR.(*corresponding author)

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Nuclear Medicine & Biology.,37(7), 785-794 ,2010 (pdf)（@Duke大学）
31．Chaipan C, Steffen I, Tsegaye TS, Bertram S, Glowacka I, Kato Y, Schmokel J, Munch J, Gerardy-Schahn R, and Pohlmann S.

Incorporation of podoplanin into human immunodeficiency virus particles released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2 and transmission to target cells

Retrovirology, 19;7(1):47, 2010 (PDF)
30．Kato Y*, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, Mansson JE, Bigner DD.(*corresponding author)

GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.

Biochem Biophys Res Commun., 391(1), 750-755, 2010 (PDF)（Duke大学での仕事）

2009

29．Kato Y*, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD(*corresponding author)

A Monoclonal Antibody IMab-1 Specifically Recognizes IDH1R132H, the Most Common Glioma-Derived Mutation.

Biochem Biophys Res Commun., 390(3), 547-551, 2009. (PDF)（Duke大学での仕事）
28．Yamanaka M, Kato Y, Angata T, Narimatsu H.

Deletion polymorphism of SIGLEC14 and its functional implications.

Glycobiology, 19(8):841-6, 2009. (PDF)
27．Kuno A, Kato Y (double first), Matsuda A, Kaneko MK, Ito H, Amano K, Chiba Y, Narimatsu H, Hirabayashi J.

Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification.

Molecular & Cellular Proteomics, 8:99-108, 2009. (PDF)

2008

26．Ogasawara S, Kaneko MK, Price JE, Kato Y*.(*corresponding author)

Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.

Hybridoma, 27(4), 259-267, 2008 (PDF)
25．Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T, Fujita N.

Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis.

Blood, 112(5), 1730-1739, 2008 (PDF)
24．Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y*(*corresponding author)

Podocalyxin expression in malignant astrocytic tumors

Biochem Biophys Res Commun. 374(2):394-8, 2008
23．Kato Y*, Hayatsu N, Kaneko MK, Ogasawara S, Hamano T, Takahashi S, Nishikawa R, Matsutani M, Mishima K, Narimatsu H.(*corresponding author)

Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors.

Biochem Biophys Res Commun., 369(4):1041-1046, 2008
22．Amano K, Chiba Y, Kasahara Y, Kato Y, Kaneko MK, Kuno A, Ito H, Kobayashi K, Hirabayashi J, Jigami Y, Narimatsu H.

Engineering of mucin-type human glycoproteins in yeast cells.

Proc Natl Acad Sci U S A., 105, 3232-3237, 2008
21．Hayatsu N, Ogasawara S, Kaneko MK, Kato Y*, Narimatsu H.(*corresponding author)

Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells.

Biochem Biophys Res Commun, 368, 217-222, 2008
20．Kato Y*, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H.(*corresponding author)

Molecular analysis of pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.

Cancer Sci, 99(1), 54-61,2008
19．Suzuki H, Kato Y* (double first), Kaneko MK, Okita Y, Narimatsu H, and Kato M.(*corresponding author)

Induction of podoplanin by transforming growth factor-β in human fibrosarcoma.

FEBS lett., 582, 341-345, 2008
18．Hasegawa Y, Kato Y* (double first), Kaneko MK, Ogasawara S, Shimazu M, Tanabe M, Kawachi S, Obara H, Shinoda M, Kitagawa Y, Narimatsu H, Kitajima M.(*corresponding author)

Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid organ transplantation.

Transplantation. 85(3):378-385, 2008

2007

17．Kaneko MK, Kato Y (double first), Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H.

Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.

FEBS Lett., 581(2):331-336, 2007
16．Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Narimatsu H, Ozaki Y.

Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells.

J Biol Chem. 282(36):25993-26001, 2007
15．Kunita A., Kashima T., Morishita Y., Fukayama M., Kato Y., Tsuruo T., Fujita N.

The platelet aggregation-inducing factor Aggrus/podoplanin promotes pulmonary metastasis.

Am J Pathol., 170(4):1337-1347, 2007

2006

14．Kato Y.*, Kaneko MK., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., Osawa M.(*corresponding author)

Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet- aggregation-stimulating domain.

Biochem Biophys Res Commun., 349(4):1301-1307, 2006
13．Kaneko MK, Kato Y, Kitano T, Osawa M.

Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor.

Gene, 378C:52-57, 2006
12．Mishima K, Kato Y*, Kaneko MK, Nishikawa R, Hirose T, Matsutani M.(*corresponding author)

Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.

Acta Neuropathol (Berl).111(5):483-488, 2006
11．Mishima, K., Kato Y*, Kaneko, MK., Nakazawa, Y., Kunita, A., Fujita, N., Tsuruo, T., Nishikawa, R., Hirose, T., Matsutani, M.(*corresponding author)

Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma.

Acta Neuropathol (Berl). 111(6):563-568. 2006

~2005

10．Kato Y., Kaneko, M., Sata, M., Fujita, N., Tsuruo, T., Osawa, M.

Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet aggregation-inducing factor in lung squamous cell carcinoma.

Tumor Biol. 26 (4) 195-200, 2005
9．Kato Y., Sasagawa, I., Kaneko, M., Osawa, M., Fujita, N., Tsuruo, T.

Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors.

Oncogene. 23, 8552-8556, 2004
8．Kaneko, M., Kato Y., Kunita, A., Fujita, N., Tsuruo, T., Osawa, M.

Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells.

J Biol. Chem. 279 ,38838-38843, 2004
7．Kato Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M. and Tsuruo, T.

Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.

J Biol. Chem. 278, 51599-51605, 2003.
6．Kaneko M, Kato Y, Osawa M.

Molecular characterization of a human monoclonal antibody to B antigen in ABO blood type.

Immunol Lett. 2003 Mar 3;86(1):45-51.
5．Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, Nakamura K, Iida A, Anazawa H, Koh N, Iwano A, Imura A, Fujimori T, Kuro-o M, Hanai N, Takeshige K, Nabeshima Y.

Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys.

Biochem Biophys Res Commun. 2000 Jan 19;267(2):597-602.
4．Kato Y, Hori S, Fujita N, Tsuruo T.

A novel anti-platelet monoclonal antibody induces mouse platelet aggregation through an Fc receptor-independent mechanism.

Biochem Biophys Res Com., 1998 Jan 14;242(2):250-5.
3．Kato Y, Fujita N, Yano H, Tsuruo T.

Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule.

Cancer Res. 1997 Jul 15;57(14):3040-5.
2．Fujita N, Kodama N, Kato Y, Lee SH, Tsuruo T.

Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases.

Exp Cell Res. 1997 May 1;232(2):400-6.
1. Fujita N, Kato Y, Naito M, Tsuruo T.

A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression.

Int J Cancer. 1996 May 16;66(4):544-50.

原著論文/英文総説

業績

プレスリリース

トピックス